Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

23
results for

"Yong Kyun Cho"

Article category

Keywords

Publication year

"Yong Kyun Cho"

Review

Steatotic liver disease

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clin Mol Hepatol 2023;29(Suppl):S261-S267.
Published online December 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0393
Non-alcoholic fatty liver disease (NAFLD) is accepted as a counterpart to alcohol-related liver disease because it is defined as hepatic steatosis without excessive use of alcohol. However, the definition of moderate alcohol consumption, as well as whether moderate alcohol consumption is beneficial or detrimental, remains controversial. In this review, the findings of clinical studies to date with high-quality evidence regarding the effects of moderate alcohol consumption in NAFLD patients were compared and summarized.

Citations

Citations to this article as recorded by  Crossref logo
  • Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
    Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Effects of moderate beer consumption on immunity and the gut microbiome in immunosuppressed mice
    Shumin HU, Hua YIN, Xiaxia LI, Minghao FAN, Huajun LI
    Bioscience of Microbiota, Food and Health.2025; 44(1): 32.     CrossRef
  • Changes in drinking levels and metabolic dysfunction-associated steatotic liver disease: a longitudinal study from the China multi-ethnic cohort study
    Ning Zhang, Jingzhong Li, Xiaofen Xie, Yifan Hu, Hongxiang Chen, Yuan Zhang, Yujie Liu, Xingren Zhu, Hao Xu, Zhenghong Wang, Kangzhuo Baima, Xuehui Zhang, Zixiu Qin, Zhimiao Yu, Xiong Xiao, Xing Zhao
    BMC Public Health.2025;[Epub]     CrossRef
  • Alcohol-associated liver disease: Natural history, management and novel targeted therapies
    Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, Ana Clemente-Sánchez, Hugo López-Pelayo, Ramón Bataller
    Clinical and Molecular Hepatology.2025; 31(Suppl): S112.     CrossRef
  • Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
    Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
    International Journal of Molecular Sciences.2025; 26(4): 1778.     CrossRef
  • Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease
    Mao Li, Bin Yu, Xiaoli Zhang, Jia Pan, Lei Tang, Yi Zhang, Ruixin Wang, Honglian Zeng, Shujuan Yang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond
    Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114.     CrossRef
  • Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD
    Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu
    Antioxidants.2025; 14(10): 1196.     CrossRef
  • Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
    Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 107.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Alcohol consumption and its association with cancer, cardiovascular, liver and brain diseases: a systematic review of Mendelian randomization studies
    Naouras Bouajila, Cloé Domenighetti, Henri-Jean Aubin, Mickael Naassila
    Frontiers in Epidemiology.2024;[Epub]     CrossRef
  • The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
    Ji-Won Park, Ki Tae Suk
    Clinical and Molecular Hepatology.2023; 29(2): 408.     CrossRef
  • Oxidative balance score is inversely associated with the incidence of non-alcoholic fatty liver disease
    A-Ra Cho, Yu-Jin Kwon, Jun-Hyuk Lee
    Clinical Nutrition.2023; 42(8): 1292.     CrossRef
  • Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
    Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao
    BMC Medicine.2023;[Epub]     CrossRef
  • Alcohol consumption and the risk of liver disease: a nationwide, population-based study
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • 9,198 View
  • 149 Download
  • 16 Web of Science
  • Crossref

Guideline

Steatotic liver disease

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401.
Published online June 22, 2021
DOI: https://doi.org/10.3350/cmh.2021.0178

Citations

Citations to this article as recorded by  Crossref logo
  • Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719
    Qinqin Qiao, Shuhua Shan, Huiqin Guo, Ning An, Jiangying Shi, Zhuoyu Li
    Food Research International.2026; 225: 118084.     CrossRef
  • Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim
    Clinical Gastroenterology and Hepatology.2025; 23(1): 114.     CrossRef
  • Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 491.     CrossRef
  • Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers
    Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang
    Journal of Physical Activity and Health.2025; 22(3): 323.     CrossRef
  • The Role of microRNA-22 in Metabolism
    Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen
    International Journal of Molecular Sciences.2025; 26(2): 782.     CrossRef
  • Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
    Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
    Gut and Liver.2025; 19(1): 116.     CrossRef
  • Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
    Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
    Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong
    Clinical Epidemiology.2025; Volume 17: 53.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
    Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin
    Heliyon.2025; 11(7): e43073.     CrossRef
  • Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study
    Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun
    JHEP Reports.2025; 7(6): 101388.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults
    Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang
    Acta Psychologica.2025; 256: 105041.     CrossRef
  • Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study
    Jisuk Yun, Young‐Sun Min
    American Journal of Industrial Medicine.2025; 68(7): 588.     CrossRef
  • Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry
    Kavindya Samarakoon, H.P. Vasantha Rupasinghe
    Journal of Food Composition and Analysis.2025; 144: 107656.     CrossRef
  • Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
  • Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
    Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun
    Scientific Reports.2025;[Epub]     CrossRef
  • Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease?
    Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros
    World Journal of Stem Cells.2025;[Epub]     CrossRef
  • The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis
    Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964.     CrossRef
  • Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
    Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
    Clinical and Molecular Hepatology.2025; 31(3): 771.     CrossRef
  • Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis
    Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan
    BMC Complementary Medicine and Therapies.2025;[Epub]     CrossRef
  • Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
    Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease
    Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling
    Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
    Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(5): 758.     CrossRef
  • Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review
    Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan
    International Journal of Molecular Sciences.2025; 26(19): 9625.     CrossRef
  • Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study
    Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min
    Journal of Clinical Medicine.2025; 14(20): 7284.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges
    Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes
    Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun
    Angiology.2024; 75(3): 219.     CrossRef
  • Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
    Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan
    Steroids.2024; 203: 109330.     CrossRef
  • Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study
    Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin
    Nutrition.2024; 128: 112579.     CrossRef
  • Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study
    Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
    Liver International.2024; 44(3): 799.     CrossRef
  • Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini
    Metabolites.2024; 14(1): 52.     CrossRef
  • Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease
    I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang
    The Journal of Nutritional Biochemistry.2024; 126: 109583.     CrossRef
  • Quality Evaluation of Metabolic-Associated Fatty Liver Disease Guidelines and Expert Consensus
    Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin
    Hormone and Metabolic Research.2024; 56(07): 509.     CrossRef
  • Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
    Xin Ding, Xu He, Bulang Tang, Tian Lan
    Chinese Medicine.2024;[Epub]     CrossRef
  • Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
    Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim
    JAMA Internal Medicine.2024; 184(4): 375.     CrossRef
  • Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial
    Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang
    Journal of Medical Internet Research.2024; 26: e49839.     CrossRef
  • Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
    Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin
    Heliyon.2024; 10(5): e27325.     CrossRef
  • Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification
    Woo Sun Rou
    Clinical Ultrasound.2024; 9(1): 1.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
    Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
    Liver International.2024; 44(6): 1448.     CrossRef
  • Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
    Yaxin Li, Yitian Guo, Shiyun Tan
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Sleep factors were associated with a higher risk of MAFLD and significant fibrosis
    Yaxin Li, Shiyun Tan
    Sleep and Breathing.2024; 28(3): 1381.     CrossRef
  • Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
    Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
    Journal of Agricultural and Food Chemistry.2024; 72(13): 7187.     CrossRef
  • Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy
    PLOS ONE.2024; 19(3): e0301126.     CrossRef
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
    Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
    Hepatology Research.2024; 54(11): 1027.     CrossRef
  • Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event
    Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin
    Diabetes & Metabolism Journal.2024; 48(3): 449.     CrossRef
  • An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors
    Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie
    BIO Web of Conferences.2024; 111: 03024.     CrossRef
  • Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis
    Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong
    Diagnostics.2024; 14(11): 1083.     CrossRef
  • Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
    Journal of Hepatology.2024; 81(5): 772.     CrossRef
  • A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease
    Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai
    Antioxidants.2024; 13(6): 746.     CrossRef
  • Emerging mRNA Technology for Liver Disease Therapy
    Ji Wang, Yile Fang, Zhiqiang Luo, Jinglin Wang, Yuanjin Zhao
    ACS Nano.2024; 18(27): 17378.     CrossRef
  • Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT
    Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi
    European Radiology.2024; 34(12): 7609.     CrossRef
  • Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice
    Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang
    Experimental Gerontology.2024; 194: 112519.     CrossRef
  • The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial
    Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu
    Nutrients.2024; 16(14): 2254.     CrossRef
  • Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
    Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni
    Hepatology International.2024; 18(S2): 922.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • Barriers to care linkage and educational impact on unnecessary MASLD referrals
    Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
    Merve Cebi, Yusuf Yilmaz
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease
    Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
    Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park
    Scientific Reports.2024;[Epub]     CrossRef
  • A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease
    Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus
    Hepatology.2024;[Epub]     CrossRef
  • Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park
    Diagnostics.2024; 14(20): 2305.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats
    Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri
    Biomedical Reports.2024;[Epub]     CrossRef
  • Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
    Yuan Yao, Yunfeng Shen
    Open Life Sciences.2023;[Epub]     CrossRef
  • Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
    Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(2): 358.     CrossRef
  • Non-Invasive Liver Fibrosis Scores Are Associated With Contrast-Associated Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention
    Hao-Ming He, Chen He, Zhe-Bin You, Si-Cheng Zhang, Xue-Qin Lin, Man-Qing Luo, Mao-Qing Lin, Li-Wei Zhang, Kai-Yang Lin, Yan-Song Guo
    Angiology.2023; 74(4): 333.     CrossRef
  • Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(7): 1873.     CrossRef
  • The association of non‐alcoholic fatty liver disease between parents and adolescent children
    Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak
    Alimentary Pharmacology & Therapeutics.2023; 57(2): 245.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2435.     CrossRef
  • Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
    Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults
    Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim
    Clinical Hypertension.2023;[Epub]     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection
    Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 431.     CrossRef
  • Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease
    Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab
    Journal of Clinical and Experimental Hepatology.2023; 13(5): 783.     CrossRef
  • Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Min-Kyu Kang, Min-Cheol Kim
    Medicina.2023; 59(2): 375.     CrossRef
  • The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
    George Chen, Bubu Banini, Albert Do, Joseph K. Lim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S319.     CrossRef
  • Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(Suppl): S220.     CrossRef
  • Global incidence and prevalence of nonalcoholic fatty liver disease
    Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
    Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
  • Non-alcoholic fatty liver disease: the pathologist’s perspective
    Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S302.     CrossRef
  • Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
    Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee
    Biomedicine & Pharmacotherapy.2023; 161: 114445.     CrossRef
  • Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
    Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong
    Scientific Reports.2023;[Epub]     CrossRef
  • Screening strategy for non-alcoholic fatty liver disease
    Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
    Clinical and Molecular Hepatology.2023; 29(Suppl): S103.     CrossRef
  • Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
    Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
    Clinical and Molecular Hepatology.2023; 29(Suppl): S157.     CrossRef
  • Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
    Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
    Metabolites.2023; 13(3): 444.     CrossRef
  • Nonalcoholic fatty liver disease and non-liver comorbidities
    Richie Manikat, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2023; 29(Suppl): s86.     CrossRef
  • Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
    Peter Konyn, Aijaz Ahmed, Donghee Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S43.     CrossRef
  • Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
    Jihyun An, Joo Hyun Sohn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S268.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
    Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
    Clinical and Molecular Hepatology.2023; 29(Suppl): S123.     CrossRef
  • Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah-Kheong Chan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S58.     CrossRef
  • Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
    Jung Hwan Yu, Han Ah Lee, Seung Up Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S136.     CrossRef
  • Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
    Georg Semmler, Christian Datz, Michael Trauner
    Clinical and Molecular Hepatology.2023; 29(Suppl): S244.     CrossRef
  • Non-alcoholic fatty liver disease: Definition and subtypes
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S5.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
    Yi-wen Shi, Jian-Gao Fan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S228.     CrossRef
  • Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
    Anja Geerts, Sander Lefere
    Clinical and Molecular Hepatology.2023; 29(Suppl): S276.     CrossRef
  • Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
    Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
    Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
  • CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis?
    Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee
    Ultrasonography.2023; 42(2): 227.     CrossRef
  • The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
    Young-Joo Jin
    Clinical and Molecular Hepatology.2023; 29(2): 414.     CrossRef
  • Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
    Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
    Clinical and Molecular Hepatology.2023; 29(2): 404.     CrossRef
  • The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
    Ji-Won Park, Ki Tae Suk
    Clinical and Molecular Hepatology.2023; 29(2): 408.     CrossRef
  • Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
    Philipp Kasper, Münevver Demir, Hans-Michael Steffen
    Clinical and Molecular Hepatology.2023; 29(2): 390.     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • The growing burden of non-alcoholic fatty liver disease on mortality
    Ju-Yeon Cho, Won Sohn
    Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
  • Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
    Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park
    Hepatology International.2023; 17(3): 626.     CrossRef
  • Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population
    Yeon Jun Kim, Yoon Shin Cho
    Genes & Genomics.2023; 45(7): 847.     CrossRef
  • Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study
    Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
    Han Ah Lee, Hwi Young Kim
    International Journal of Molecular Sciences.2023; 24(11): 9324.     CrossRef
  • Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD
    Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(3): 322.     CrossRef
  • Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
    Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
    Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
    Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
    Ultrasonography.2023; 42(3): 421.     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
    Gut and Liver.2023; 17(4): 610.     CrossRef
  • The correlation between NAFLD and serum uric acid to serum creatinine ratio
    Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas
    PLOS ONE.2023; 18(7): e0288666.     CrossRef
  • Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B
    Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Alimentary Pharmacology & Therapeutics.2023; 58(7): 704.     CrossRef
  • Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
    Ho Soo Chun
    Gut and Liver.2023; 17(4): 485.     CrossRef
  • KASL clinical practice guidelines for management of autoimmune hepatitis 2022

    Clinical and Molecular Hepatology.2023; 29(3): 542.     CrossRef
  • Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply
    Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon
    Gut and Liver.2023; 17(4): 663.     CrossRef
  • Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid
    PLOS ONE.2023; 18(7): e0288820.     CrossRef
  • Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim
    Trials.2023;[Epub]     CrossRef
  • Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data
    Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Statins for treatment of fatty liver disease: Recent advances
    Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi
    World Chinese Journal of Digestology.2023; 31(16): 659.     CrossRef
  • MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
    Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
  • The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients
    Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed
    European Journal of Hybrid Imaging.2023;[Epub]     CrossRef
  • Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
    Gi-Ae Kim, Joon Ho Moon, Won Kim
    Clinical and Molecular Hepatology.2023; 29(4): 831.     CrossRef
  • Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
    Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han
    Infectious Diseases and Therapy.2023; 12(10): 2387.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
    Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He
    Hepatology Communications.2023;[Epub]     CrossRef
  • Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
    Ji Cheol Bae
    The Journal of Korean Diabetes.2023; 24(3): 107.     CrossRef
  • Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production
    Dong Yun Kim, Jun Yong Park, Heon Yung Gee
    Experimental & Molecular Medicine.2023; 55(11): 2332.     CrossRef
  • Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
    Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
    Hepatology.2023; 78(6): 1858.     CrossRef
  • Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study
    Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek
    Journal of Yeungnam Medical Science.2023; 40(Suppl): S47.     CrossRef
  • The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults
    Jisuk Yun, Soon-Chan Kwon
    Toxics.2023; 11(12): 965.     CrossRef
  • Alcohol consumption and the risk of liver disease: a nationwide, population-based study
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
    T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
  • Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity
    Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park
    Korean Journal of Family Practice.2023; 13(4): 240.     CrossRef
  • Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Diabetologia.2022; 65(3): 518.     CrossRef
  • Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
    Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
    Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
  • Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious
    Suprabhat Giri, Harish Darak, Sunil Kasturi
    Digestive Diseases and Sciences.2022; 67(10): 4962.     CrossRef
  • Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
    Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do
    Biomedicines.2022; 10(3): 550.     CrossRef
  • Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
    Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Hepatology.2022; 76(2): 492.     CrossRef
  • The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight?
    Sae Hwan Lee
    The Korean Journal of Gastroenterology.2022; 79(3): 138.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(4): 101344.     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
    Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour
    International Journal of Molecular Sciences.2022; 23(8): 4305.     CrossRef
  • Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
    Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae
    Clinical and Molecular Hepatology.2022; 28(2): 196.     CrossRef
  • Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
    Youn Huh, Yoon Jeong Cho, Ga Eun Nam
    Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17.     CrossRef
  • Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease
    Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1624.     CrossRef
  • The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study
    Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease
    Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim
    Healthcare.2022; 10(5): 850.     CrossRef
  • Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease
    Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee
    Biomedicines.2022; 10(6): 1216.     CrossRef
  • Risk of liver fibrosis in patients with prediabetes and diabetes mellitus
    Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu
    PLOS ONE.2022; 17(6): e0269070.     CrossRef
  • Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study
    Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(5): 101362.     CrossRef
  • Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): 1746.     CrossRef
  • Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Annals of Surgical Treatment and Research.2022; 102(6): 353.     CrossRef
  • A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia
    Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2022; 43(2): 184.     CrossRef
  • Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study
    Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang
    Scientific Reports.2022;[Epub]     CrossRef
  • Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data
    Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim
    International Journal of Environmental Research and Public Health.2022; 19(14): 8398.     CrossRef
  • Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
    Jung Il Lee
    Gut and Liver.2022; 16(4): 497.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
    Hankil Lee, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2154.     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): E121.     CrossRef
  • Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
    Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
    Journal of Hepatology.2022; 77(6): 1482.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis
    Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim
    International Journal of Environmental Research and Public Health.2022; 19(16): 10444.     CrossRef
  • Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study
    Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang
    Annals of Occupational and Environmental Medicine.2022;[Epub]     CrossRef
  • Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
    Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease
    Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Healthcare.2022; 10(11): 2268.     CrossRef
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
    Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
    Biomedicine & Pharmacotherapy.2022; 156: 113952.     CrossRef
  • Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo
    Gut and Liver.2022; 16(6): 952.     CrossRef
  • The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2022; 28(4): 814.     CrossRef
  • Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
    Soon Sun Kim, Jae Youn Cheong
    Clinical and Molecular Hepatology.2022; 28(4): 802.     CrossRef
  • Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease
    Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee
    Medicine.2022; 101(37): e30527.     CrossRef
  • A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease
    Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim
    The Journal of Internal Korean Medicine.2022; 43(4): 680.     CrossRef
  • Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2022; 28(4): 933.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Pengyu Yao, Yajuan Liu
    Molecules.2022; 28(1): 272.     CrossRef
  • The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
    Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
    Current Oncology.2022; 30(1): 48.     CrossRef
  • Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63.     CrossRef
  • Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
    Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung
    Diagnostics.2021; 11(12): 2233.     CrossRef
  • Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus
    Kiyoung Lim, Minkyu Kang, Junggil Park
    Nutrients.2021; 13(10): 3400.     CrossRef
  • Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
    Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila
    PLOS ONE.2021; 16(8): e0255822.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial
    Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim
    Nutrients.2021; 13(12): 4453.     CrossRef
  • Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim
    Cancers.2021; 13(18): 4567.     CrossRef
  • 32,523 View
  • 1,305 Download
  • 197 Web of Science
  • Crossref

Original Article

Viral hepatitis

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol 2021;27(2):346-359.
Published online January 25, 2021
DOI: https://doi.org/10.3350/cmh.2020.0307
Background/Aims
Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients.
Methods
Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV).
Results
Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group.
Conclusions
BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
    Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
    Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Wo
    Clinical and Molecular Hepatology.2025; 31(3): 810.     CrossRef
  • Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights From a Nationwide Cohort Study
    Hyun Bin Choi, Jae Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
    Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient
    Jong Chul Kim, Hye Young Lee, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Juhee Won, Soree Park, Na Yeon Kim, Jae Jin Shin, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo, Kyun-Hwan Kim
    Biomedicines.2022; 10(2): 282.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
    Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Jong Chul Kim, Soree Park, Nayeon Kim, Byengjune Jae, Kyun-Hwan Kim
    Biomedicines.2022; 10(7): 1637.     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
    Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
    Clinical and Molecular Hepatology.2021; 27(3): 402.     CrossRef
  • 10,176 View
  • 268 Download
  • 16 Web of Science
  • Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Alcohol-related liver disease

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
Jong Hwa Choi, Won Sohn, Yong Kyun Cho
Clin Mol Hepatol 2020;26(4):662-669.
Published online September 25, 2020
DOI: https://doi.org/10.3350/cmh.2020.0163
Nonalcoholic fatty liver disease (NAFLD) is defined by fat accumulation in liver that is not caused by excessive alcohol consumption. Safe limits of alcohol consumption in NAFLD are usually defined as alcohol consumption of less than 210 g per week for men and 140 g per week for women (30 g/day in men, 20 g/day in women) and alcohol consumption below safe limits is generally regarded as moderate alcohol consumption. Many studies have investigated the effects of moderate alcohol consumption on NAFLD patients. Some studies showed that moderate alcohol consumption prevented the progression of fibrosis in the liver, whereas other reports showed worsening of fibrosis in the liver based on serologic, radiologic and liver biopsy findings compared with effects on total abstainers. NAFLD is also thought to be a hepatic manifestation of metabolic syndrome, and when combined with excessive alcohol consumption results in the development of components of metabolic syndrome and systemic harmful effects. The effects of moderate alcohol consumption on NAFLD have yet to be established.

Citations

Citations to this article as recorded by  Crossref logo
  • In‐depth assessment of steatotic liver disease awareness in high‐risk groups
    Murat Özdede, Alper Tuna Güven, Burcu Çelik Eroğlu
    Journal of Evaluation in Clinical Practice.2025;[Epub]     CrossRef
  • Association between menopause, body composition, and nonalcoholic fatty liver disease: A prospective cohort in northern China
    Chenlu Yang, Shuohua Chen, Baoyu Feng, Ying Lu, Yanhong Wang, Wei Liao, Shouling Wu, Li Wang
    Maturitas.2025; 192: 108148.     CrossRef
  • The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial
    Maryam Nilghaz, Amir Sadeghi, Glareh Koochakpoor, Hossein Poustchi, Navideh Khodadadi, Behnaz Narimani, Maryam Ghods, Mahshad Shafiee, Mohammad Reza Shahparvari, Azita Hekmatdoost
    Scientific Reports.2025;[Epub]     CrossRef
  • Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches
    Thea Chevalley, Marion Dübi, Laurent Fumeaux, Maria Serena Merli, Alexandre Sarre, Natacha Schaer, Umberto Simeoni, Catherine Yzydorczyk
    Cells.2025; 14(6): 467.     CrossRef
  • Life-threatening risk factors contribute to the development of diseases with the highest mortality through the induction of regulated necrotic cell death
    Zsuzsa Muszka, Viktória Jenei, Rebeka Mácsik, Evgeniya Mezhonova, Silina Diyab, Réka Csősz, Attila Bácsi, Anett Mázló, Gábor Koncz
    Cell Death & Disease.2025;[Epub]     CrossRef
  • The fasting plasma glucose to high-density lipoprotein cholesterol ratio: a novel index for identifying NAFLD
    Changhui Yu, Shiming He, Nan Peng, Maobin Kuang, Xin Huang, Chao Wang, Guotai Sheng, Wei Wang, Guobo Xie, Yang Zou
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
    Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang
    Clinical and Molecular Hepatology.2025; 31(2): 548.     CrossRef
  • Evaluating the regional and demographic variables in alcoholic liver disease-related mortality trends in the United States from 1999 to 2020: A cross sectional study
    Malik Saad Hayat, Muhammad Mukarram Shoaib, Sara Sohail, Shahzaib Ahmed, Fatima Shahid, Hadia Ahmad, Mohammad Rayyan Naseer, Muhammad Mohtasham Shoaib, Raheel Ahmed
    Medicine.2025; 104(14): e41988.     CrossRef
  • Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
  • Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights
    Carlo Acierno, Fannia Barletta, Alfredo Caturano, Riccardo Nevola, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Luca Rinaldi
    Nutrients.2025; 17(13): 2229.     CrossRef
  • Prebiotic and Probiotic Foods in MASLD: Microbiome-Mediated Therapeutic Strategies
    Cui Beiming, Liu Yujie, Hui-Eun Chang Joyce, Chen Jieying, Xu Jiahang, Teoh Jian-Peng, Loong Ho Chun
    Synthetic Biology and Engineering.2025; 3(4): 10018.     CrossRef
  • Association of remnant cholesterol and newly diagnosed early‐onset type 2 diabetes mellitus in Chinese population: A retrospective cross‐sectional study
    Wenjing Dong, Shiju Yan, Han Chen, Jian Zhao, Zengqiang Zhang, Weijun Gu
    Journal of Diabetes.2024;[Epub]     CrossRef
  • Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
    Metabolism.2024; 152: 155789.     CrossRef
  • Oxidative Balance Score and New-Onset Type 2 Diabetes Mellitus in Korean Adults without Non-Alcoholic Fatty Liver Disease: Korean Genome and Epidemiology Study-Health Examinees (KoGES-HEXA) Cohort
    Mid-Eum Moon, Dong Hyuk Jung, Seok-Jae Heo, Byoungjin Park, Yong Jae Lee
    Antioxidants.2024; 13(1): 107.     CrossRef
  • The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review
    Jong-Won Kim, Yu Ji Kim
    Life Sciences.2024; 344: 122547.     CrossRef
  • Evaluating the relative importance of different blood pressure indices in screening for NAFLD: a survey report based on a health examination population
    Chong Hu, Ziqi Yu, Changli Wei, Guotai Sheng, Jianyong Chen, Yang Zou
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions
    Ravi Adinarayan Somabattini, Sahla Sherin, Bhukya Siva, Neelanjan Chowdhury, Satheesh Kumar Nanjappan
    Life Sciences.2024; 351: 122806.     CrossRef
  • Oxidative balance score as a useful predictive marker for new-onset type 2 diabetes mellitus in Korean adults aged 60 years or older: The Korean Genome and Epidemiologic Study–Health Examination (KoGES-HEXA) cohort
    Mid-Eum Moon, Dong Hyuk Jung, Seok-Jae Heo, Byoungjin Park, Yong Jae Lee
    Experimental Gerontology.2024; 193: 112475.     CrossRef
  • Lipoprotein Combine Index as a Better Marker for NAFLD Identification Than Traditional Lipid Parameters
    Jiajun Qiu, Xin Huang, Maobin Kuang, Ruijuan Yang, Jiachong Li, Guotai Sheng, Yang Zou
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 2583.     CrossRef
  • The newly proposed plasma-glycosylated hemoglobin A1c/High-Density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination popu
    Shiming He, Song Lu, Changhui Yu, Maobin Kuang, Jiajun Qiu, Guotai Sheng, Yang Zou
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
    Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu
    Hepatology International.2024; 18(S2): 897.     CrossRef
  • Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups
    Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu
    Gut and Liver.2024; 18(5): 888.     CrossRef
  • The Clínica Universidad de Navarra-Body Adiposity Estimator index is a reliable tool for screening metabolic dysfunction-associated steatotic liver disease: an analysis from a gender perspective
    Chao Wang, Xin Huang, Shiming He, Maobin Kuang, Guobo Xie, Guotai Sheng, Yang Zou
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study
    Ludovico Abenavoli, Rocco Spagnuolo, Giuseppe Guido Maria Scarlata, Maria Luisa Gambardella, Luigi Boccuto, Nahum Méndez-Sánchez, Francesco Luzza
    Life.2024; 14(10): 1226.     CrossRef
  • Prevalence of metabolic dysfunction‐associated steatotic liver disease in people living with HIV and on antiretroviral treatment: A systematic review and meta‐analysis protocol
    Amogelang Sedibe, Khanyisa Maswanganyi, Nomusa C. Mzimela, Mlindeli Gamede
    Health Science Reports.2024;[Epub]     CrossRef
  • Alcohol consumption and its association with cancer, cardiovascular, liver and brain diseases: a systematic review of Mendelian randomization studies
    Naouras Bouajila, Cloé Domenighetti, Henri-Jean Aubin, Mickael Naassila
    Frontiers in Epidemiology.2024;[Epub]     CrossRef
  • Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician
    Carolyn Newberry, Sonal Kumar
    Nutrition in Clinical Practice.2023; 38(1): 70.     CrossRef
  • The role of predicted lean body mass and fat mass in non-alcoholic fatty liver disease in both sexes: Results from a secondary analysis of the NAGALA study
    Maobin Kuang, Ruijuan Yang, Qiyang Xie, Nan Peng, Song Lu, Guobo Xie, Shuhua Zhang, Yang Zou
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Evaluation and analysis of novel germline variants in ethanol metabolism pathway genes predisposition to liver disease
    Partha Pratim Das, Manash Jyoti Kalita, Anjan Jyoti Talukdar, Faraz Mohd Khan, Kalpajit Dutta, Simanta Kalita, Nabajyoti Goswami, Gautam Hazarika, Gourinath Samudrala, Mohammed ghaznavi Idris, Sangit Dutta, Subhash Medhi
    Gene.2023; 873: 147451.     CrossRef
  • Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease
    Jingfei Chen, Yingjie Su, Xin Su, Fei Luo
    Diabetes Research and Clinical Practice.2023; 201: 110733.     CrossRef
  • MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
    Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
  • A non-linear relationship between triglyceride glucose waist circumference and nonalcoholic fatty liver disease in a Japanese population: a secondary analysis
    Xiaojie He, Xinyue Huang, Yafang Qian, Ting Sun
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply
    Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon
    Gut and Liver.2023; 17(4): 663.     CrossRef
  • The newly proposed alanine aminotransferase to high-density lipoprotein cholesterol ratio has shown effectiveness in identifying non-alcoholic fatty liver disease
    Jiajun Qiu, Maobin Kuang, Ruijuan Yang, Changhui Yu, Shiming He, Guotai Sheng, Yang Zou
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Association of mean arterial pressure with non-alcoholic fatty liver disease: results from the NAGALA study
    Xinghui Li, Huijian Yang, Guobo Xie, Maobin Kuang, Guotai Sheng, Yang Zou
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Old age as a risk factor for liver diseases: Modern therapeutic approaches
    Milena Georgieva, Charilaos Xenodochidis, Natalia Krasteva
    Experimental Gerontology.2023; 184: 112334.     CrossRef
  • Adherence to a Traditional Mexican Diet Is Associated with Lower Hepatic Steatosis in US-Born Hispanics of Mexican Descent with Overweight or Obesity
    Melissa Lopez-Pentecost, Martha Tamez, Josiemer Mattei, Elizabeth T. Jacobs, Cynthia A. Thomson, David O. Garcia
    Nutrients.2023; 15(23): 4997.     CrossRef
  • Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population
    Jiawang Zou, Hailan Xiong, Huimin Zhang, Chong Hu, Song Lu, Yang Zou
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease
    Yang Zou, Chong Hu, Maobin Kuang, Yuliang Chai
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference
    Tae Kyung Yoo, Byeong Kil Oh, Mi Yeon Lee, Ki-Chul Sung
    Scientific Reports.2022;[Epub]     CrossRef
  • Effects of moderate ethanol consumption as a function of n-6:n-3 dietary ratio on lipid profile, inflammation, and liver function in mice
    Kristine Giltvedt, Luciano S. Voutour, Brianna Tursellino, Alexandra Zella, Susan M. Brasser, Mee Young Hong
    International Journal of Cardiology Cardiovascular Risk and Prevention.2022; 14: 200132.     CrossRef
  • Association between hypertriglyceridemic-waist phenotype and non-alcoholic fatty liver disease: a general population-based study
    Ming Yang, Yaqin Xu, Chong Hu, Shuhua Zhang, Maobin Kuang, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population
    Maobin Kuang, Song Lu, Qiyang Xie, Nan Peng, Shiming He, Changhui Yu, Jiajun Qiu, Guotai Sheng, Yang Zou
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Utility of traditional and non-traditional lipid indicators in the diagnosis of nonalcoholic fatty liver disease in a Japanese population
    Song Lu, Maobin Kuang, Jinjing Yue, Chong Hu, Guotai Sheng, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR‐mediated inhibition of autophagy under hyperlipidemic conditions
    Heeseung Oh, Seung Yeon Park, Wonjun Cho, A. M. Abd El‐Aty, Ahmet Hacimuftuoglu, Chang Hyuk Kwon, Ji Hoon Jeong, Tae Woo Jung
    Journal of Cellular Physiology.2022; 237(11): 4226.     CrossRef
  • The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease
    Maobin Kuang, Guotai Sheng, Chong Hu, Song Lu, Nan Peng, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
    Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2022; 28(4): 790.     CrossRef
  • Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population
    Rongsheng Wang, Longlong DAI, Yanjia Zhong, Guobo Xie
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study
    Yang Zou, Jianyun Lan, Yanjia Zhong, Shuo Yang, Huimin Zhang, Guobo Xie
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease
    Guotai Sheng, Song Lu, Qiyang Xie, Nan Peng, Maobin Kuang, Yang Zou
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)
    Wayne Eskridge, John M. Vierling, Wayne Gosbee, Gabriella A. Wan, May-Linh Hyunh, Henry E. Chang, Daisuke Tokuhara
    PLOS ONE.2021; 16(11): e0260320.     CrossRef
  • 15,104 View
  • 192 Download
  • 53 Web of Science
  • Crossref

Editorial

Steatotic liver disease

  • 8,708 View
  • 109 Download

Review

Steatotic liver disease

Recent research trends and updates on nonalcoholic fatty liver disease
Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn, On behalf of the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)
Clin Mol Hepatol 2019;25(1):1-11.
Published online August 8, 2018
DOI: https://doi.org/10.3350/cmh.2018.0037
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver–related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease
    Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman
    Biomedicines.2025; 13(3): 644.     CrossRef
  • Impact of sleeve gastrectomy on the course of metabolic associated fatty liver disease
    Ragaey Ahmad Eid, Dina Attia, Asmaa Srour Soliman, Eman Ahmed Abd Elmaogod, Eman Mohammed AbdelSalam, Ahmed Mohamed Rashad, Ahmed Safaa Ahmed Sayed, Tamer Mohamed Nabil
    Indian Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): e226.     CrossRef
  • Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
    Clinical and Molecular Hepatology.2025; 31(2): e186.     CrossRef
  • Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease
    Hiroki Nishikawa, Tomohiro Nishikawa, Akira Fukuda, Kosuke Ushiro, Masahiro Matsui, Saori Onishi, Soo Ki Kim, Akira Asai
    Internal Medicine.2025; 64(21): 3078.     CrossRef
  • Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study
    Mengyan Xu, Rui Gong, Jiao Xie, Sanping Xu, Shi Wang
    Nutrition & Metabolism.2025;[Epub]     CrossRef
  • Liver involvement in Gaucher disease in children: A literature review and clinical observations
    G.V. Volynets, G.B. Movsisyan, A.S. Potapov, A.I. Khavkin, A.V. Nikitin, T.A. Skvortsova, E.A. Morozova, V.M. Rogozhina
    Russian Journal of Evidence-Based Gastroenterology.2025; 14(2): 78.     CrossRef
  • PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children
    Hengpan Yao, Zhiyi Xia, Yijing Liu, MengJun Dong, Kairui Yang, Fang Zhou
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
    Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin
    Current Drug Therapy.2024; 19(1): 20.     CrossRef
  • Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases
    Arianna Ferro, Gabriele Saccu, Simone Mattivi, Andrea Gaido, Maria Beatriz Herrera Sanchez, Shafiul Haque, Lorenzo Silengo, Fiorella Altruda, Marilena Durazzo, Sharmila Fagoonee
    Biomolecules.2024; 14(3): 277.     CrossRef
  • Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
    Joo Hyun Oh, Dae Won Jun
    Gut and Liver.2024; 18(2): 197.     CrossRef
  • Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
    Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani-Gentilucci
    Journal of Physiology and Biochemistry.2023; 79(4): 851.     CrossRef
  • Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia
    Joon Ho, Eunhwa Kim, Myeongjee Lee, Inkyung Jung, Young Suk Jo, Jandee Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • Global incidence and prevalence of nonalcoholic fatty liver disease
    Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
    Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
  • Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria
    Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang
    Journal of Clinical Medicine.2023; 12(6): 2126.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus
    Qian Gao, Lei Feng, Weiling Zhou, Xiaoli Li, Lanzi Yin, Yuan Wang
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2345.     CrossRef
  • Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
    Mah I Kan Changez, Maryam Mubeen, Monezahe Zehra, Inara Samnani, Aniqa Abdul Rasool, Anmol Mohan, Um Ul Wara, Usha Tejwaney, Vikash Kumar
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Association between PNPLA3 and TM6SF2 gene polymorphisms and non-alcoholic fatty liver disease patients in Kazakhstan
    Ainura Amirkulova, Gulmira Derbissalina, Valeriy Benberin, Nasrulla Shanazarov, Gulshara Abildinova, Doskhan Kozhakhmet, Helena Katchman
    Electronic Journal of General Medicine.2023; 20(6): em546.     CrossRef
  • The empirical dietary inflammatory pattern score and the risk of nonalcoholic fatty liver disease and cirrhosis
    Maryam K. Ibrahim, Robert M. Wilechansky, Prasanna K. Challa, Xuehong Zhang, Edward Giovannucci, Meir Stampfer, Andrew T. Chan, Tracey G. Simon
    Hepatology Communications.2023;[Epub]     CrossRef
  • Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease
    Apostolis PAPAEFTHYMIOU, Michael DOULBERIS, Kyriaki KARAFYLLIDOU, Eleftherios CHATZIMICHAEL, Georgia DERETZI, Aristomenis K. EXADAKTYLOS, Fotios SAMPSONAS, Athanasios GELASAKIS, Spyros I. PAPAMICHOS, Georgios KOTRONIS, Dimitra GIALAMPRINOU, Elisabeth VARD
    Minerva Endocrinology.2023;[Epub]     CrossRef
  • The experience of the "Nicolae Malaxa" Clinical Hospital Bucharest, 2021-2022: non-alcoholic hepatic steatosis – etiological and risk profile
    Gabriela-Carmen Obilişteanu, Alexandru-Mihai Ştefănescu, Florin-Mihai Lungana, Nicolae Runcanu
    Medic.ro.2023; 5(155): 8.     CrossRef
  • Molecular Docking Study of Phytosterols in Lygodium microphyllum Towards SIRT1 and AMPK, the in vitro Brine Shrimp Toxicity Test, and the Phenols and Sterols Levels in the Extract
    Putri Anggreini, Hadi Kuncoro, Sri Sumiwi, Jutti Levita
    Journal of Experimental Pharmacology.2023; Volume 15: 513.     CrossRef
  • Both full length‐cholesteryl ester transfer protein and exon 9‐deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes
    Yan Liu, Daniel Mihna, Lahoucine Izem, Richard E. Morton
    Lipids.2022; 57(1): 69.     CrossRef
  • Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis
    Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Xiao Luo, Lu Long, Xuehong Zhang, Andrew T. Chan, Tracey G. Simon
    Clinical Nutrition.2022; 41(2): 356.     CrossRef
  • Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Diabetologia.2022; 65(3): 518.     CrossRef
  • Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma
    Mizelle D'Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Surgical Oncology.2022; 41: 101730.     CrossRef
  • MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
    Young-Sun Lee, Ji Eun Lee, Hyon-Seung Yi, Young Kul Jung, Dae Won Jun, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Baek-hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, Juneyoung Lee, Soon Ho Um, Kwan Soo Byun
    Hepatology International.2022; 16(2): 316.     CrossRef
  • DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES)
    Young Kyung Ko, Hayeon Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim
    Current Issues in Molecular Biology.2022; 44(3): 1149.     CrossRef
  • Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
    Yuna Kim, Eugene Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Mi Kyung Kim, Hye Soon Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee, Seung Up Kim
    Gut and Liver.2022; 16(2): 290.     CrossRef
  • Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study
    Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(5): 101362.     CrossRef
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
    Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
    Biomedicine & Pharmacotherapy.2022; 156: 113952.     CrossRef
  • Environmental exposure to organophosphate esters and suspected non-alcoholic fatty liver disease among US adults: A mixture analysis
    Haisheng Chai, Weiye Hu, Yaoyao Dai, Xiaohan Zhu, Ping'an Qian, Junfeng Zhu
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • A Nomogram Based on Preoperative Lab Tests, BMI, ICG-R15, and EHBF for the Prediction of Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
    Deyao Zhang, Yangxun Pan, Zhenyun Yang, Huilan Zeng, Xin Wang, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Minshan Chen, Dandan Hu
    Journal of Clinical Medicine.2022; 12(1): 324.     CrossRef
  • Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation
    Ju Won Lee, Seung Ha Park
    Journal of Affective Disorders.2021; 278: 259.     CrossRef
  • Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
    Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Diabetes and its Complications.2021; 35(1): 107747.     CrossRef
  • Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
    Gwyneth Soon, Aileen Wee
    Clinical and Molecular Hepatology.2021; 27(1): 44.     CrossRef
  • Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes
    Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Young Dae Kim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1703.     CrossRef
  • From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
    Clinical and Molecular Hepatology.2021; 27(2): 257.     CrossRef
  • Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang
    Scientific Reports.2021;[Epub]     CrossRef
  • Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
    Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Gut and Liver.2021; 15(1): 117.     CrossRef
  • Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
    Kwang Min Kim, Ji-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon
    Scientific Reports.2021;[Epub]     CrossRef
  • Nonalcoholic Fatty Liver Disease: A Global Perspective
    Wei-Kei Wong, Wah-Kheong Chan
    Clinical Therapeutics.2021; 43(3): 473.     CrossRef
  • Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver
    Min-Kyu Kang, Jung-Hun Baek, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Yu-Rim Lee, Keun Hur, Gyeonghwa Kim, Hye-Won Lee, Man-Hoon Han, Joon-Hyuk Choi, Soo-Young Park, Jung-Gil Park
    Diagnostics.2021; 11(6): 1061.     CrossRef
  • Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
    Tae Hyung Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim, Eunjung Ko, Sun Young Yim, Young Kul Jung, SeongHee Kang, Moon Young Kim, Hayeon Kim, Baek-hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Scientific Reports.2021;[Epub]     CrossRef
  • Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease
    Sanghwa Kim, Ah Young Lee, Myung-Haing Cho
    Heliyon.2021; 7(3): e06452.     CrossRef
  • Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
    Min-Kyu Kang, Jung-Gil Park
    Diagnostics.2021; 11(5): 854.     CrossRef
  • Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease
    Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Metabolic disease as a risk of hepatocellular carcinoma
    Naoshi Nishida
    Clinical and Molecular Hepatology.2021; 27(1): 87.     CrossRef
  • Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
    Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila
    PLOS ONE.2021; 16(8): e0255822.     CrossRef
  • Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease
    Jung Gil Park, Jinho Jung, Kritin K. Verma, Min Kyu Kang, Egbert Madamba, Scarlett Lopez, Aed Qas Yonan, Amy Liu, Ricki Bettencourt, Claude Sirlin, Rohit Loomba
    Alimentary Pharmacology & Therapeutics.2021; 53(9): 1030.     CrossRef
  • Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma
    Daryl Ramai, Jameel Singh, Janice Lester, Shahab R. Khan, Saurabh Chandan, Nicola Tartaglia, Antonio Ambrosi, Gaetano Serviddio, Antonio Facciorusso
    Alimentary Pharmacology & Therapeutics.2021; 53(9): 977.     CrossRef
  • Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women
    S. H. Park, Y. E. Park, J. Lee, J. H. Choi, N. Y. Heo, J. Park, T. O. Kim, Y. S. Moon, H. K. Kim, H. J. Jang, H. Y. Park, C.-H. Jeong, K. T. Suk, D. J. Kim
    Climacteric.2020; 23(2): 173.     CrossRef
  • Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
    Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim
    Clinical and Molecular Hepatology.2020; 26(2): 209.     CrossRef
  • Liver involvement in patients with Gaucher disease types I and III
    Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz
    Molecular Genetics and Metabolism Reports.2020; 22: 100564.     CrossRef
  • Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators
    Seung Ha Park, Dong Joon Kim, Lindsay D. Plank
    European Journal of Clinical Nutrition.2020; 74(10): 1401.     CrossRef
  • Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017
    Mi Jin Kim, Kyung Jae Lee
    BMC Pediatrics.2020;[Epub]     CrossRef
  • Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
    Young-Sun Lee, Yang Jae Yoo, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, In Hee Kim, Soo Yeon Lee, Baek-Hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, So Young Kwon, Soon Ho Um, Kwan Soo Byun
    Clinical and Translational Gastroenterology.2020; 11(4): e00157.     CrossRef
  • Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
    Soung Won Jeong
    Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef
  • Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
    Hyuk Soo Eun
    Clinical and Molecular Hepatology.2020; 26(2): 236.     CrossRef
  • Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database
    Boram Cha, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Seon Young Ahn, Suk Bae Kim, Il Han Song
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
    Young Chang, Jun Il Kim, Bora Lee, Sang Gyune Kim, Min Jung Jung, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo
    Clinical and Molecular Hepatology.2020; 26(3): 318.     CrossRef
  • Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study
    Bertha Araceli Marin-Alejandre, Itziar Abete, J. Ignacio Monreal, Mariana Elorz, Alberto Benito-Boillos, José Ignacio Herrero, Iñigo Navarro-Blasco, Josep A. Tur, Narcisa M. Bandarra, M. Angeles Zulet, J. Alfredo Martinez
    Journal of Clinical Lipidology.2020; 14(6): 837.     CrossRef
  • Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
    Min Kyu Kang, Jung Gil Park, Min Cheol Kim
    Yonsei Medical Journal.2020; 61(10): 860.     CrossRef
  • Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis
    Jung Gil Park, Gyeonghwa Kim, Se Young Jang, Yu Rim Lee, Eunhye Lee, Hye Won Lee, Man-Hoon Han, Jae Min Chun, Young Seok Han, Jun Sik Yoon, Min Kyu Kang, Young Oh Kweon, Won Young Tak, Soo Young Park, Keun Hur
    Life.2020; 10(10): 230.     CrossRef
  • Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women
    Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Po-Hong Liu, Wenjie Ma, Xuehong Zhang, Manol Jovani, Mingyang Song, Andrew T. Chan, Tracey G. Simon
    Metabolism.2020; 113: 154398.     CrossRef
  • Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
    Soung Won Jeong
    Diabetes & Metabolism Journal.2020; 44(5): 640.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans
    Kan Chen, Jianbo Ma, Xiaoyuan Jia, Wen Ai, Zhongren Ma, Qiuwei Pan
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2019; 1871(1): 117.     CrossRef
  • Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B
    Beom Kyung Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2019; 50(3): 333.     CrossRef
  • Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study
    Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee
    PLOS ONE.2019; 14(10): e0223678.     CrossRef
  • The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis
    Sezgin VATANSEVER, Zehra Betül PAKÖZ
    Marmara Medical Journal.2019; 32(1): 44.     CrossRef
  • 23,056 View
  • 743 Download
  • 77 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up
Hojung Jung, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim, Hyun Pyo Hong
Clin Mol Hepatol 2018;24(4):424-429.
Published online November 14, 2017
DOI: https://doi.org/10.3350/cmh.2017.0032
Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report
    Takeshi Koujima, Yoshikatsu Endo, Takeharu Yamamoto, Toshifumi Tada, Kazuhiko Morii, Shinichiro Nakamura, Kyohei Kai
    Kanzo.2020; 61(5): 255.     CrossRef
  • 14,442 View
  • 183 Download
  • 1 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol 2017;23(4):323-330.
Published online September 5, 2017
DOI: https://doi.org/10.3350/cmh.2017.0005
Background/Aims
Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance.
Methods
Two hundred fifty eight CHB patients who underwent ETV treatment in our institution from July 2007 to May 2013 were included.
Results
Eight (3.1%) patients developed genotypic resistance to ETV during the follow-up period. The patterns of genotypic resistance to ETV were as follows: L180M + M204V + S202G (n=3); M204I + V173M (n=1); I169V + V173M (n=1); L180M + M204V + V173L (n=1); L180M + M204V + V173L + M250V (n=1); M204I + V214A + P237H (n=1). The cumulative occurrence rates of genotypic resistance to ETV were not significantly different between CHB patients with prior nucleos(t)tide analogues (NA) exposure (NA experienced, n=56) and NA naïve patients (n=202, P=0.823 by log rank comparison). Older age, higher baseline log10hepatitis B virus-deoxynucleic acid (log10HBV-DNA), higher log10HBV-DNA at 3, 6, 12 and 24 months after baseline, and complete virologic response (CVR, undetectable serum HBV-DNA by polymerase chain reaction 6 months after ETV treatment) were significant contributors to the development of genotypic resistance to ETV. Multivariate analyses showed higher log10HBV-DNA 6 months after baseline and absence of CVR were independent and significant contributors to the development of ETV resistance.
Conclusions
Clinical characteristics of patients who developed ETV resistance were higher log10HBV-DNA 6 months after baseline and absence of CVR during the ETV treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Specific association and independent predictive value of HBV RNA in the disease progression of hepatitis B with low-level viremia
    Liang Xu, Bin Yin, Dandan Chen, Xia Xiong, Yongfeng Yang, Xuping Wu
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102648.     CrossRef
  • Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study
    Yinong Feng, Li Zhou, Shaoyuan Shi, Zehong Wang, Xuanxuan Wang, Fan Du
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment
    Zhong-Bin Li, Dan-Dan Chen, Yun-Fei Jia, Qing-Juan He, Li Cui, Feng-Xia Du, Yao-Jie Kang, Xin Feng, Mengwen He, Xue-Yuan Jin, Jing Chen, Yudong Wang, Dong Ji, George Lau, Shu-Gao Wu
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Risk factors of low‐level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study
    He Chen, Juan‐Juan Fu, Li Li, Xia Wang, Xiu‐Cheng Pan
    Journal of Gastroenterology and Hepatology.2024; 39(1): 180.     CrossRef
  • A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
    Sheila F. Lumley, Marion Delphin, Jolynne F. Mokaya, Cedric C.S. Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O. Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C.
    Journal of Clinical Virology.2024; 174: 105711.     CrossRef
  • The urgency to expand the antiviral indications of general chronic hepatitis B patients
    Ping Fan, Lan-Qing Li, En-Qiang Chen
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Research Progress of Low-Level Viraemia in Patients with Chronic Hepatitis B
    祥运 张
    Advances in Clinical Medicine.2023; 13(12): 20083.     CrossRef
  • The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years
    Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei
    Infection, Genetics and Evolution.2021; 89: 104706.     CrossRef
  • Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR
    Jingjing Liang, Xinmiao Liang, Hong Ma, Leng Nie, Ying Tian, Guang Chen, Yu Wang
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
    Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
    Wellcome Open Research.2020; 5: 151.     CrossRef
  • Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
    Hans L. Tillmann, Gbeminiyi Samuel
    Expert Opinion on Pharmacotherapy.2019; 20(7): 873.     CrossRef
  • Entecavir

    Reactions Weekly.2018; 1688(1): 98.     CrossRef
  • Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
    Joon Yeul Nam, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2017; 23(4): 311.     CrossRef
  • 10,511 View
  • 185 Download
  • 10 Web of Science
  • Crossref

Viral hepatitis

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi
Clin Mol Hepatol 2016;22(3):350-358.
Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0019
Background/Aims
To analyze the effects of preexisting lamivudine (LAM) resistance and applying antiviral treatment (adefovir [ADV] add-on LAM combination treatment) on long-term treatment outcomes, and comparing the clinical outcomes of antiviral-naïve chronic hepatitis B patients receiving entecavir (ETV) monotherapy.
Methods
This study enrolled 73 antiviral-naïve patients who received 0.5-mg ETV as an initial therapy and 54 patients who received ADV add-on LAM combination treatment as a rescue therapy from July 2006 to July 2010.
Results
During 24-month treatments, the decreases in serum log10HBV-DNA values (copies/mL) were significantly greater in the antiviral-naïve patients treated with ETV than the patients receiving ADV add-on LAM combination treatment. The biochemical response rates for alanine aminotransferase normalization at 6 months (ETV) and 12 months (ADV add-on LAM) were 90.4% (66/73) and 77.8% (42/54), respectively (P=0.048). A Kaplan-Meier analysis indicated that the rates of serologic response, viral breakthrough, and emergence of genotypic resistance did not differ significantly between the two patient groups. There were also no significant intergroup differences in the rates of disease progression (PD) and new development of hepatocellular carcinoma (HCC).
Conclusions
The long-term clinical outcomes of antiviral-naïve patients treated with ETV and LAM-resistant patients receiving ADV add-on LAM combination treatment were comparable in terms of the emergence of HCC and disease progression.

Citations

Citations to this article as recorded by  Crossref logo
  • Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis
    Si-Si Yang, Cheng-Wei Cai, Xue-Qing Ma, Jia Xu, Cheng-Bo Yu
    Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 507.     CrossRef
  • 11,641 View
  • 142 Download
  • 1 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

Primary squamous cell carcinoma of the liver: a case report
Tae Kyung Yoo, Byung Ik Kim, Eun Na Han, Dong Hyung Kim, Jung Hee Yoo, Seung Jae Lee, Yong Kyun Cho, Hong Joo Kim
Clin Mol Hepatol 2016;22(1):177-182.
Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.177
Primary squamous cell carcinoma (SCC) of the liver is very rare, and few cases have been reported in Korea. Primary SCC of the liver is known to be associated with hepatic cysts and intrahepatic stones. A 71-year-old male was admitted to our hospital, and a abdominal computed tomography scan revealed a 10 × 6 cm mass in the liver. Analysis of a biopsy sample suggested SCC, and so our team performed a thorough workup to find the primary lesion, which was revealed hepatoma as a pure primary SCC of the liver with multiple distant metastases. The patient was treated with one cycle of radiotherapy, transferred to another hospital for hospice care, and then died 1 month after discharge.

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical Outcomes of Hepatic Squamous Cell Carcinoma With Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation: A Case Report
    Ryogo Minami, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Kiminori Kimura
    Cureus.2025;[Epub]     CrossRef
  • Immunotherapy for primary squamous cell carcinoma of the liver: A case report
    Jian Jiang, Guomin Dong, Suoni Li, Jiequn Ma, Jie Bai, Jinzi Hui, Hongbian Gao, Zheng Zhao
    Oncology Letters.2025; 29(6): 1.     CrossRef
  • Primary hepatic squamous cell carcinoma with pseudoachalasia treated with TACE: Case report and literature review
    Yang He, Hang Du, An Tianzhi
    Radiology Case Reports.2025; 20(10): 4906.     CrossRef
  • Primary Hepatic Squamous Cell Carcinoma: A Case Report
    Manal Lyagoubi, Chourouq Mehdaoui, Anass Haloui, Nassira Karish, Zahi Ismaili, Amal Bennani
    Cureus.2024;[Epub]     CrossRef
  • A case report of primary intrahepatic adeno squamous cell cholangiocarcinoma
    Fionn Woulfe, Michael Devine, Brian Hayes, Rory Crotty, Adrian O'Sullivan
    International Journal of Surgery Case Reports.2024; 124: 110366.     CrossRef
  • Diagnostic value of imaging modalities in primary squamous cell carcinoma of the liver
    Yuxuan Song, Jiahong Shi, Xiujuan Zhang, Meng Qiao, Zhixia Sun, Siyu Tian
    Journal of Clinical Ultrasound.2023; 51(5): 887.     CrossRef
  • Immunotherapy as adjuvant therapy for a patient with adenosquamous carcinoma of the intrahepatic bile duct: A case report and literature review
    Jun Feng, Aimaiti Yasen, Tianxing Dai, Runbin Liang, Zhihong Liao, Ping He, Zhihong Lin, Guoying Wang
    Liver Research.2023; 7(2): 156.     CrossRef
  • Unusual Case of Primary Hepatic Squamous Carcinoma on 18F-FDG PET/CT
    Wei Li, Zhidong Liu, Rusen Zhang
    Clinical Nuclear Medicine.2023; 48(12): e596.     CrossRef
  • Primary hepatic squamous cell carcinoma: case report and systematic review of the literature
    Lin Zhao, Yan Zhou, Jianmin Ding, Zhengyi Qin, Hongyu Zhou, Xiang Jing
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Primary squamous cell carcinoma of the liver: A case report
    Li-Min Kang, Di-Ping Yu, Yong Zheng, Ya-Hao Zhou
    World Journal of Clinical Cases.2022; 10(19): 6744.     CrossRef
  • Primary squamous cell carcinoma of liver. First case report from Pakistan and South Asia
    Muhammad Atiq, Ahmed Siddique Ammar, Rabia Mahmood Ali, Siraj Haider, Imran Ahmed, Faisal Saud Dar
    International Journal of Surgery Case Reports.2022; 99: 107655.     CrossRef
  • Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report
    Hsu-Lin Lee, Chun-Kai Fu, Liang-Yu Chien, Li-Mien Chen
    Medicina.2022; 58(12): 1864.     CrossRef
  • Primary squamous cell carcinoma of the liver: a case report
    Yu Sun, Guangyu Jin
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Primary intrahepatic squamous cell carcinoma in a sika deer
    Kazuya MATSUDA, Junji YAMADA, Shun KOGAME, Ryo MURATA, Yuto SANO
    Journal of Veterinary Medical Science.2020; 82(2): 135.     CrossRef
  • Primary squamous cell carcinoma of the liver: an unexpected pathological finding
    Fabio Tuminello, Davide Castiglione, Giuseppe Broggi, Giada Maria Vecchio, Antonio Basile, Stefano Puleo, Antonio Pesce
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Primary hepatic squamous cell carcinoma with abdominal incision metastasis after hepatectomy
    Jia-Xi Mao, Fei Teng, Hang Yuan, Cong Liu, Hong Fu, Ke-Yan Sun, Guo-Shan Ding, Wen-Yuan Guo
    Hepatobiliary & Pancreatic Diseases International.2019; 18(2): 194.     CrossRef
  • 15,134 View
  • 141 Download
  • 17 Web of Science
  • Crossref

Original Articles

Steatotic liver disease

Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study
Kil Woo Lee, Ki Bae Bang, Eun Jung Rhee, Heon Ju Kwon, Mi Yeon Lee, Yong Kyun Cho
Clin Mol Hepatol 2015;21(4):372-378.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.372
Background/Aims

Hypothyroidism is reported to contribute to the development of nonalcoholic fatty liver disease (NAFLD). We compared the risk of the development of NAFLD among three groups with different thyroid hormonal statuses (control, subclinical hypothyroidism, and overt hypothyroidism) in a 4-year retrospective cohort of Korean subjects.

Methods

Apparently healthy Korean subjects without NAFLD and aged 20-65 years were recruited (n=18,544) at health checkups performed in 2008. Annual health checkups were applied to the cohort for 4 consecutive years until December 2012. Based on their initial serum-free thyroxine (fT4) and thyroid-stimulating hormone (TSH) levels, they were classified into control, subclinical hypothyroidism (TSH >4.2 mIU/L, normal fT4), and overt hypothyroidism (TSH >4.2 mIU/L, fT4 <0.97 ng/dL) groups. NAFLD was diagnosed on the basis of ultrasonography findings.

Results

NAFLD developed in 2,348 of the 18,544 subjects, representing an overall incidence of 12.7%: 12.8%, 11.0%, 12.7% in the control, subclinical hypothyroidism, and overt hypothyroidism groups, respectively. The incidence of NAFLD did not differ significantly with the baseline thyroid hormonal status, even after multivariate adjustment (subclinical hypothyroidism group: hazard ratio [HR]=0.965, 95% confidence interval [CI]=0.814-1.143, P=0.67; overt hypothyroidism group: HR=1.255, 95% CI=0.830-1.899, P=0.28).

Conclusions

Our results suggest that the subclinical and overt types of hypothyroidism are not related to an increased incidence of NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Raman spectroscopic characterization of liver steatosis and fibrosis in a 2D and 3D in vitro thyroxine-treated hypothyroid cellular model
    S. Maurotti, B. Scopacasa, F. Scionti, R. Pujia, M. Frosina, A. Mirarchi, N. Geirola, R. Mare, T. Montalcini, P. Candeloro, L. Tirinato, A. Pujia
    Molecular and Cellular Endocrinology.2026; 611: 112679.     CrossRef
  • Actions of thyroid hormones and thyromimetics on the liver
    Rohit A. Sinha, Eveline Bruinstroop, Paul M. Yen
    Nature Reviews Gastroenterology & Hepatology.2025; 22(1): 9.     CrossRef
  • Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment
    Sicheng Pu, Binbin Zhao, Yuxuan Jiang, Xuejiao Cui
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Association of free triiodothyronine and total triiodothyronine with nonalcoholic fatty liver disease: from National Health and Nutrition Examination Survey and Mendelian randomization study
    Wei Hao, Lanlan Chen, Ting Li, Guoyue Lv
    European Journal of Gastroenterology & Hepatology.2025; 37(7): 864.     CrossRef
  • Research Advances in the Correlation between Hypothyroidism and Metabolic Associated Fatty Liver Disease
    羽 龙
    Advances in Clinical Medicine.2025; 15(05): 795.     CrossRef
  • Evidence on the link between hypothyroidism and non-alcoholic fatty liver disease: an updated systematic review
    Nazanin Pourseyedi, Sara Arefhosseini, Helda Tutunchi, Mehrangiz Ebrahimi-Mameghani
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery
    Shizhang Wei, Yuan Dong, Yanping Wang, Guohui Li, Yanling Zhao, Ruimao Zheng
    Pharmacological Research.2025; 221: 107972.     CrossRef
  • Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
    Joanna Betlejewska, Joanna Hubska, Zuzanna Roszkowska, Aleksandra Maciejczyk, Dominika Bachurska, Jan Domański, Maciej Miarka, Joanna Raszeja-Wyszomirska, Małgorzata Bobrowicz, Urszula Ambroziak
    Biomedicines.2025; 13(10): 2500.     CrossRef
  • Association between thyroid function and metabolic associated fatty liver disease: a systemic review and meta-analysis
    Wei Xiong, Hua Fan, Jiake Tang, Qingwen Yu, Ziyi Xin, Ting Tang, Xiyun Rao, Lanlan Feng, Yongmin Shi, Xuhan Tong, Xinyan Fu, Xingwei Zhang, Mingwei Wang, Wentao Gan
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta‐Analysis
    Gedion Yilma Amdetsion, Chun-Wei Pan, Hiwot Tebeje, Abhin Sapkota, Shreyas Nandyal, Vikram Kotwal, Fortofoiu Mircea-Catalin
    International Journal of Hepatology.2025;[Epub]     CrossRef
  • The reciprocal relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis of about 39 million individuals
    Ariyan Ayati Firoozabadi, Iman Elahi Vahed, Pouyan Lotfi, Adel Geshani, Ali Keshavarzian, Maryam Moftakhar, Mahkameh Razaghi, Zahra Rasouli, Mahtab Montazeri, Mohammad Ali Mansournia, Massoud Vosough, Mohammad Rahmanian, Afagh Hassanzadeh Rad
    PLOS One.2025; 20(12): e0338413.     CrossRef
  • Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease
    Shuo Wang, Ding Xia, Hong Fan, Zhenqiu Liu, Ruilin Chen, Chen Suo, Tiejun Zhang
    JGH Open.2024;[Epub]     CrossRef
  • Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
    Yan Yang, Jiyuan Xiao, Wen Qiu, Luxia Jiang
    Hormone and Metabolic Research.2024; 56(10): 697.     CrossRef
  • Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
    Alessandro Mantovani, Alessandro Csermely, Josh Bilson, Niccolò Borella, Scoccia Enrico, Barbara Pecoraro, Emigela Shtembari, Riccardo Morandin, Stergios A Polyzos, Luca Valenti, Herbert Tilg, Christopher D Byrne, Giovanni Targher
    Gut.2024; 73(9): 1554.     CrossRef
  • Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom
    Mohammad Shafi Kuchay, Scott Isaacs, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(5): 103034.     CrossRef
  • Relationship between thyroid hormone levels and metabolic dysfunction associated steatotic liver disease in patients with type 2 diabetes: A clinical study
    Tingbo Bi
    Medicine.2024; 103(26): e38643.     CrossRef
  • Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial
    Miriam Sommer-Ballarini, Thu-Huong Nguyen, Laura Pletsch-Borba, Charlotte Wernicke, Frank Tacke, Tanja Schwerdtle, Denny Pellowski, Jürgen Machann, Joachim Spranger, Eva Katrin Wirth, Knut Mai
    European Journal of Endocrinology.2024; 191(2): 183.     CrossRef
  • Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
    Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
    Eunyoung Lee, Hannelie Korf, Antonio Vidal-Puig
    Journal of Hepatology.2023; 78(5): 1048.     CrossRef
  • The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease
    Yingying Hu, Fan Zhou, Fang Lei, Lijin Lin, Xuewei Huang, Tao Sun, Weifang Liu, Xingyuan Zhang, Jingjing Cai, Zhi-Gang She, Hongliang Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Interrelation Between Hypothyroidism and Non-alcoholic Fatty Liver Disease, a Cross-sectional Study
    Sarah Elshinshawy, Hemmat Elhaddad, Shereen Abdel Alem, Olfat Shaker, Randa Salam, Ayman Yosry, Ibrahim Elebrashy
    Journal of Clinical and Experimental Hepatology.2023; 13(4): 638.     CrossRef
  • Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?
    Barbara Janota, Elżbieta Szczepańska, Brygida Adamek, Ewa Janczewska
    World Journal of Hepatology.2023; 15(5): 641.     CrossRef
  • Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
    Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, Michael Charlton
    Journal of Hepatology.2023; 79(6): 1524.     CrossRef
  • Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study
    Ashraf Almomani, Asif Ali Hitawala, Prabhat Kumar, Sura Alqaisi, Dana Alshaikh, Motasem Alkhayyat, Imad Asaad
    World Journal of Hepatology.2022; 14(3): 551.     CrossRef
  • The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum
    Maria V. Deligiorgi, Dimitrios T. Trafalis
    Journal of Clinical Medicine.2022; 11(12): 3417.     CrossRef
  • Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function
    Yuanyuan Zhang, Juyi Li, Huaizhen Liu
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Liver Stiffness in Obese Hypothyroid Patients Taking Levothyroxine
    Roberta Pujia, Elisa Mazza, Tiziana Montalcini, Franco Arturi, Antonio Brunetti, Antonio Aversa, Stefano Romeo, Maria Perticone, Angela Sciacqua, Arturo Pujia
    Medicina.2022; 58(7): 946.     CrossRef
  • Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults
    Li-Juan Tan, Sangah Shin
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease
    Eleonore Fröhlich, Richard Wahl
    Metabolites.2022; 12(8): 718.     CrossRef
  • NAFLD and thyroid function: pathophysiological and therapeutic considerations
    Erifili Hatziagelaki, Stavroula A. Paschou, Martin Schön, Theodora Psaltopoulou, Michael Roden
    Trends in Endocrinology & Metabolism.2022; 33(11): 755.     CrossRef
  • Association of Subclinical Hypothyroidism with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Vahid Sheikhi, Zahra Heidari
    Advanced Biomedical Research.2022; 11(1): 124.     CrossRef
  • Association between Thyroid Hormones and Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Obese Individuals Undergoing Bariatric Surgery
    Narges Ashraf Ganjooei, Tannaz Jamialahmadi, Mohsen Nematy, Najeeb Zaheer Shah, Sara Jangjoo, Nima Emami, Ali Jangjoo, Reyhaneh Faridnia, Mona Alidadi, Thozhukat Sathyapalan, Amirhossein Sahebkar
    Middle East Journal of Digestive Diseases.2022; 14(4): 410.     CrossRef
  • The relationship between non-alcoholic fatty liver disease and hypothyroidism
    Xiaoxu Zeng, Bin Li, Yang Zou
    Medicine.2021; 100(17): e25738.     CrossRef
  • Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study
    Shizheng Qiu, Peigang Cao, Yu Guo, Haoyu Lu, Yang Hu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population
    Alba Martínez-Escudé, Guillem Pera, Anna Costa-Garrido, Lluís Rodríguez, Ingrid Arteaga, Carmen Expósito-Martínez, Pere Torán-Monserrat, Llorenç Caballería
    Journal of Clinical Medicine.2021; 10(13): 2907.     CrossRef
  • Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
    Rafael S. Rios, Kenneth I. Zheng, Ming-Hua Zheng
    Chinese Medical Journal.2021; 134(24): 2911.     CrossRef
  • The Association Between Coffee Consumption and Nonalcoholic Fatty Liver Disease in the South Korean General Population
    Li‐Juan Tan, Hyein Jung, Seong‐Ah Kim, Sangah Shin
    Molecular Nutrition & Food Research.2021;[Epub]     CrossRef
  • The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)
    Roberta D'Ambrosio, Irene Campi, Marco Maggioni, Riccardo Perbellini, Enza Giammona, Roberta Stucchi, Marta Borghi, Elisabetta Degasperi, Annalisa De Silvestri, Luca Persani, Laura Fugazzola, Pietro Lampertico, Pavel Strnad
    PLOS ONE.2021; 16(4): e0249614.     CrossRef
  • Study on the independent effect of thyroid hormone based on uric acid level on NAFLD
    Guanqun Chao, Liying Chen
    Journal of Health, Population and Nutrition.2021;[Epub]     CrossRef
  • Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand
    Rajvi Gor, Nabeel A Siddiqui, Ransirini Wijeratne Fernando, Archana Sreekantan Nair, Janan Illango, Mushrin Malik, Pousette Hamid
    Cureus.2021;[Epub]     CrossRef
  • Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
    Maria Mavromati, François R. Jornayvaz
    International Journal of Molecular Sciences.2021; 22(23): 12797.     CrossRef
  • Hypothyroidism and nonalcoholic fatty liver disease – a chance association?
    Simonetta Lugari, Alessandro Mantovani, Fabio Nascimbeni, Amedeo Lonardo
    Hormone Molecular Biology and Clinical Investigation.2020;[Epub]     CrossRef
  • Relación entre el hipotiroidismo y el hígado graso no alcohólico en una población española
    Alba Martínez Escudé, Guillem Pera, Ingrid Arteaga, Carmen Expósito, Lluís Rodríguez, Pere Torán, Llorenç Caballeria
    Medicina Clínica.2020; 154(1): 1.     CrossRef
  • Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population
    Alba Martínez Escudé, Guillem Pera, Ingrid Arteaga, Carmen Expósito, Lluís Rodríguez, Pere Torán, Llorenç Caballeria
    Medicina Clínica (English Edition).2020; 154(1): 1.     CrossRef
  • Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
    Tomislav Kizivat, Ivana Maric, Dunja Mudri, Ines Bilic Curcic, Dragan Primorac, Martina Smolic
    Journal of Clinical and Translational Hepatology.2020; 8(3): 1.     CrossRef
  • Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
    Daniela Maria Tanase, Evelina Maria Gosav, Ecaterina Neculae, Claudia Florida Costea, Manuela Ciocoiu, Loredana Liliana Hurjui, Claudia Cristina Tarniceriu, Mariana Floria
    International Journal of Molecular Sciences.2020; 21(16): 5927.     CrossRef
  • Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms
    Ze-Yu Wu, Yi-Ling Li, Bing Chang
    World Journal of Gastroenterology.2020; 26(44): 6909.     CrossRef
  • The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor
    Xiaofu Zhang, Ruyi Li, Yingjie Chen, Yuning Dai, Ling Chen, Lei Qin, Xingbo Cheng, Yan Lu
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
    Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, Simonetta Lugari, Giovanni Targher
    Digestive and Liver Disease.2019; 51(4): 462.     CrossRef
  • NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
    Amedeo Lonardo, Alessandro Mantovani, Simonetta Lugari, Giovanni Targher
    International Journal of Molecular Sciences.2019; 20(11): 2841.     CrossRef
  • Thyroid dysfunction in obese adults in relation to nonalcoholic fatty liver disease
    Fatema Abu Bakr Abdel-Moez, Ghada A. Mohamed, Wael A. Abbas, Mohamed A. A. Abozaid, Shymaa Mohammed
    The Egyptian Journal of Internal Medicine.2019; 31(4): 629.     CrossRef
  • Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment
    P. Manka, J.D. Coombes, R. Boosman, K. Gauthier, S. Papa, W.K. Syn
    Cancer Letters.2018; 419: 175.     CrossRef
  • Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies
    Alessandro Mantovani, Giorgio Grani
    Digestive Diseases and Sciences.2018; 63(7): 1970.     CrossRef
  • Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Alessandro Mantovani, Fabio Nascimbeni, Amedeo Lonardo, Giacomo Zoppini, Enzo Bonora, Christos S. Mantzoros, Giovanni Targher
    Thyroid.2018; 28(10): 1270.     CrossRef
  • Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis
    Zeqi Guo, Miaomiao Li, Bing Han, Xingshun Qi
    Digestive and Liver Disease.2018; 50(11): 1153.     CrossRef
  • Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015
    Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Moo-Il Kang, Bong-Yun Cha, Min-Hee Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • New trends on obesity and NAFLD in Asia
    Jian-Gao Fan, Seung-Up Kim, Vincent Wai-Sun Wong
    Journal of Hepatology.2017; 67(4): 862.     CrossRef
  • Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
    Weiwei He, Xiaofei An, Ling Li, Xiaoqing Shao, Qian Li, Qiuming Yao, Jin-an Zhang
    Frontiers in Endocrinology.2017;[Epub]     CrossRef
  • Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis
    Veeravich Jaruvongvanich, Anawin Sanguankeo, Sikarin Upala
    European Thyroid Journal.2017; 6(4): 208.     CrossRef
  • 13,321 View
  • 183 Download
  • 58 Web of Science
  • Crossref

Steatotic liver disease

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea
Eun Haeng Jeong, Dae Won Jun, Yong Kyun Cho, Young Gil Choe, Seungho Ryu, Seung Min Lee, Eun Chul Jang
Clin Mol Hepatol 2013;19(3):266-272.
Published online September 30, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.3.266
Background/Aims

The prevalence of nonalcoholic fatty liver disease (NAFLD) in Korea has increased recently. The aim of the present study was to determine the regional differences in the prevalence and characteristics of NAFLD.

Methods

From January 2009 to December 2010, 161,891 Seoul and Gyeonggi-do residents receiving a health examination at our institution were enrolled in this cross-sectional study. After applying exclusion criteria, the data of 141,610 subjects (80,943 males, 60,667 females) were analyzed. The presence of NAFLD was established by ultrasound examination.

Results

The overall prevalence of NAFLD was 27.3% (38.3% in men, 12.6% in women). When standardized according to age, area, and sex, the prevalence of NAFLD was 25.2%. The age and area standardized prevalence of NAFLD was higher for men (34.4%) than for women (12.2%; P<0.001). The overall prevalence of NAFLD was higher in Gyeonggi-do (27.7%) than in Seoul (26.9%; P<0.001). Among the men, the prevalence of NAFLD was higher in Gyeonggi-do (39.2%) than in Seoul (37.4%; P<0.001), while for the women it was higher in Seoul (13.2%) than in Gyeonggi-do (12.0%; P<0.001).

Conclusions

The regional prevalence of NAFLD differed between Seoul and Gyeonggi-do. Further studies are needed to establish the etiology of this difference.

Citations

Citations to this article as recorded by  Crossref logo
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Enhancing Rectal Cancer Staging: Integrating Abbreviated Liver MRI into Standard Rectal MRI Protocols for Improved Diagnostic Utility
    Hyunjin Lee, Mi Jeong Kim, Jaehyuk Yi, Jin Hyuk Paek, Seong Kyu Baek, Woon Kyung Jeong, Byoung Je Kim
    Journal of the Korean Society of Radiology.2025; 86(5): 761.     CrossRef
  • Geographic diversity of human liver cancers mirrors global social inequalities
    Luis Cano, Fabien Foucher, Orlando Musso
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
    Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah
    Metabolites.2025; 15(5): 299.     CrossRef
  • Association between smoking status and non-alcoholic fatty liver disease
    Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Marwan Al-Nimer
    PLOS One.2025; 20(6): e0325305.     CrossRef
  • Epigenetic information loss is a common feature of multiple diseases and aging
    Naor Sagy, Chieh Chang, Maayan Gal, Daniel Z. Bar
    GeroScience.2025;[Epub]     CrossRef
  • Sugar-sweetened beverage consumption and metabolic dysfunction-associated steatotic liver disease: a beverage type-specific analysis using Korea National Health and Nutrition Examination Survey
    Hong Jae Jeon, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Ha Neul Kim, Hei-Gwon Choi, Jaehee Seo, Hyuk Soo Eun, Sukyoung Jung
    Epidemiology and Health.2025; 47: e2025038.     CrossRef
  • Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction
    Hee Jun Park, Sunyoung Lee, Jae Seung Lee
    Abdominal Radiology.2024; 49(9): 3036.     CrossRef
  • Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis
    Yaqi Xue, Yang Peng, Litian Zhang, Yi Ba, Gang Jin, Ge Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease
    Anshul Sharma, Hae-Jeung Lee
    Antioxidants.2024; 13(11): 1389.     CrossRef
  • Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
    Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee
    Biomedicine & Pharmacotherapy.2023; 161: 114445.     CrossRef
  • Treatment of Autoimmune Hepatitis
    Ja Kyung Kim
    The Korean Journal of Gastroenterology.2023; 81(2): 72.     CrossRef
  • Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness
    Pegah Golabi, Vasily Isakov, Zobair M. Younossi
    Clinics in Liver Disease.2023; 27(2): 173.     CrossRef
  • Non-alcoholic fatty liver disease: Definition and subtypes
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S5.     CrossRef
  • Risk of Metabolic Syndrome and Fatty Liver Diseases in Gastric Cancer Survivors: A Propensity Score-Matched Analysis
    Sang Jo Han, Su Jung Baik, Young Hoon Yoon, Jie Hyun Kim, Hye Sun Lee, Soyoung Jeon, Hyojin Park
    The Korean Journal of Gastroenterology.2023; 81(4): 154.     CrossRef
  • KASL clinical practice guidelines for management of autoimmune hepatitis 2022

    Clinical and Molecular Hepatology.2023; 29(3): 542.     CrossRef
  • Association of changes in body mass index and waist circumference with cardiovascular risk in non-alcoholic fatty liver disease: A nationwide study
    Se Young Jang, Hwa Jung Kim, Jun Young Chang
    Digestive and Liver Disease.2023; 55(11): 1509.     CrossRef
  • Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Choungwon Jung, Soyoung Park, Hyunah Kim, Han Eol Jeong
    PLOS ONE.2023; 18(11): e0294423.     CrossRef
  • The Clinical Diagnosis-Based Nationwide Epidemiology of Metabolic Dysfunction-Associated Liver Disease in Korea
    Nam-Hun Lee, Seok-Ju Jeong, Jing-Hua Wang, Yu-Jin Choi, Hyeon-Muk Oh, Jung-Hyo Cho, Yo-Chan Ahn, Chang-Gue Son
    Journal of Clinical Medicine.2023; 12(24): 7634.     CrossRef
  • Management of non-alcoholic fatty liver disease in patients with sarcopenia
    Ching-Sheng Hsu, Jia-Horng Kao
    Expert Opinion on Pharmacotherapy.2022; 23(2): 221.     CrossRef
  • The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study
    Yu-Guang Chen, Chih-Wei Yang, Chi-Hsiang Chung, Ching-Liang Ho, Wei-Liang Chen, Wu-Chien Chien
    Hepatology International.2022; 16(4): 807.     CrossRef
  • Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications
    Nguyen H. Tran
    Current Oncology Reports.2022; 24(2): 187.     CrossRef
  • Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
    Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae
    Clinical and Molecular Hepatology.2022; 28(2): 196.     CrossRef
  • SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
    Trends in Endocrinology & Metabolism.2022; 33(6): 424.     CrossRef
  • Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction
    Jaehyuk Choi, YoungRok Choi, Su young Hong, Sanggyun Suh, Kwangpyo Hong, Eui Soo Han, Jeong-Moo Lee, Suk Kyun Hong, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Annals of Surgical Treatment and Research.2022; 102(6): 353.     CrossRef
  • Nonalcoholic Fatty Liver Disease: Current Global Burden
    Mohamed El-Kassas, Joaquín Cabezas, Paula Iruzubieta Coz, Ming-Hua Zheng, Juan Pablo Arab, Abeer Awad
    Seminars in Liver Disease.2022; 42(03): 401.     CrossRef
  • Regional factors associated with the prevalence of metabolic syndrome: Focusing on the role of healthcare providers
    Kyu‐Tae Han, Seung Ju Kim
    Health & Social Care in the Community.2021; 29(1): 104.     CrossRef
  • Non-alcoholic Fatty Liver Disease in Asian Indian Adolescents and Young Adults
    Thaharullah Shah Mehreen, Ranjani Harish, Rajan Kamalesh, Ranjit Mohan Anjana, Viswanathan Mohan
    Journal of Diabetology.2021; 12(2): 218.     CrossRef
  • Urinary Phthalate Levels Associated with the Risk of Nonalcoholic Fatty Liver Disease in Adults: The Korean National Environmental Health Survey (KoNEHS) 2012–2014
    Yun-Jung Yang, Taehyen Kim, Yeon-Pyo Hong
    International Journal of Environmental Research and Public Health.2021; 18(11): 6035.     CrossRef
  • KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
    Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Wo
    Clinical and Molecular Hepatology.2021; 27(3): 363.     CrossRef
  • Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
    Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • The Association Between Coffee Consumption and Nonalcoholic Fatty Liver Disease in the South Korean General Population
    Li‐Juan Tan, Hyein Jung, Seong‐Ah Kim, Sangah Shin
    Molecular Nutrition & Food Research.2021;[Epub]     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
    Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
  • Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults
    Inhwan Lee, Jeonghyeon Kim, Hyunsik Kang
    International Journal of Environmental Research and Public Health.2020; 17(11): 3902.     CrossRef
  • Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
    Dae Ho Lee
    Endocrinology and Metabolism.2020; 35(2): 243.     CrossRef
  • Fruit and vegetable consumption and non-alcoholic fatty liver disease among Korean adults: a prospective cohort study
    Seong-Ah Kim, Sangah Shin
    Journal of Epidemiology and Community Health.2020; 74(12): 1035.     CrossRef
  • Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998–2035
    Seo Young Kang, Ye-Jee Kim, Hye Soon Park
    Journal of Clinical Medicine.2020; 9(8): 2626.     CrossRef
  • The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Yock Young Dan, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Paya
    Hepatology International.2020; 14(6): 889.     CrossRef
  • Association between high fatty liver index and development of colorectal cancer: a nationwide cohort study with 21,592,374 Korean
    Yoon Jin Choi, Dong Ho Lee, Kyung-Do Han
    The Korean Journal of Internal Medicine.2020; 35(6): 1354.     CrossRef
  • Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review
    Shagufta Akhtar, Azhar Khan
    Advanced Journal of Graduate Research.2020; 9(1): 46.     CrossRef
  • The changing epidemiology of liver diseases in the Asia–Pacific region
    Martin C. S. Wong, Jason L. W. Huang, Jacob George, Junjie Huang, Colette Leung, Mohammed Eslam, Henry L. Y. Chan, Siew C. Ng
    Nature Reviews Gastroenterology & Hepatology.2019; 16(1): 57.     CrossRef
  • Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
    Soo Lim, Marja‐Riitta Taskinen, Jan Borén
    Obesity Reviews.2019; 20(4): 599.     CrossRef
  • Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
    Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee
    Diabetes & Metabolism Journal.2019; 43(1): 31.     CrossRef
  • Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects
    Yeojun Yun, Han-Na Kim, Eun-ju Lee, Seungho Ryu, Yoosoo Chang, Hocheol Shin, Hyung-Lae Kim, Tae Hun Kim, Kwon Yoo, Hwi Young Kim, Ming-Lung Yu
    PLOS ONE.2019; 14(3): e0213692.     CrossRef
  • The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke
    Minyoul Baik, Seung Up Kim, Hyo Suk Nam, Ji Hoe Heo, Young Dae Kim
    Frontiers in Neurology.2019;[Epub]     CrossRef
  • The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects
    Jee Hee Yoo, Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Chang Hee Jung, Joong‐Yeol Park, Ohk‐Hyun Ryu, Hong‐Kyu Kim, Woo Je Lee
    Clinical Endocrinology.2019; 91(2): 271.     CrossRef
  • Pharmacological Activities of Alisma orientale against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature Review
    Eunsol Choi, Eungyeong Jang, Jang-Hoon Lee
    Evidence-Based Complementary and Alternative Medicine.2019; 2019: 1.     CrossRef
  • The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease
    Young-Kyu Kim, Oh-Sung Kwon, Kyu Hee Her
    Medicine.2019; 98(27): e16018.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Eun-Jung Rhee
    Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
  • Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
    Zobair Younossi, Quentin M. Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi
    Nature Reviews Gastroenterology & Hepatology.2018; 15(1): 11.     CrossRef
  • Non‐alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study
    Yang Won Min, Youngha Kim, Geum‐Youn Gwak, Seonhye Gu, Danbee Kang, Soo Jin Cho, Eliseo Guallar, Juhee Cho, Dong Hyun Sinn
    Journal of Gastroenterology and Hepatology.2018; 33(5): 1053.     CrossRef
  • Moderate to severe vasomotor symptoms are risk factors for non-alcoholic fatty liver disease in postmenopausal women
    Ki-Jin Ryu, Hyuntae Park, Yong Jin Kim, Kyong Wook Yi, Jung Ho Shin, Jun Young Hur, Tak Kim
    Maturitas.2018; 117: 22.     CrossRef
  • Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men
    Yoon Jin Choi, Dong Ho Lee, Kyung-Do Han, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Giovanni Targher
    PLOS ONE.2018; 13(9): e0201308.     CrossRef
  • Clinical Effectiveness of Acupuncture in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review
    Joon Hyun, Joo-bok Lee, So-yeon Kim, Chang-woo Han
    The Journal of Internal Korean Medicine.2018; 39(6): 1206.     CrossRef
  • Nonalcoholic fatty liver disease in Asia: emerging perspectives
    Wai-Kay Seto, Man-Fung Yuen
    Journal of Gastroenterology.2017; 52(2): 164.     CrossRef
  • Association between a High-fat Low-carbohydrate Diet and Non-alcoholic Fatty Liver Disease: Truth or Myth?
    Hyunwoo Oh, Jaehee Ahn, Dae Won Jun
    The Korean Journal of Medicine.2017; 92(2): 112.     CrossRef
  • External validation of the non‐alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients
    Dae Won Jun, Sang Gyune Kim, Sang Hoon Park, So‐Young Jin, Ji Sung Lee, Jin‐Woo Lee, Moon Young Kim, Dae Hee Choi, Yong Kyun Cho, Jong Eun Yeon, Joo Hyun Sohn
    Journal of Gastroenterology and Hepatology.2017; 32(5): 1094.     CrossRef
  • Emerging Gastrointestinal and Liver Diseases in Asia Pacific: Implications to Health Care in the Region (World Gastroenterology Organization: Asian Pacific Association of Gastroenterology Distinguished Global Lecture 2015)
    Khean-Lee Goh
    Journal of Clinical Gastroenterology.2017; 51(6): 479.     CrossRef
  • An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Ching-Sheng Hsu, Jia-Horng Kao
    Expert Review of Gastroenterology & Hepatology.2017; 11(8): 759.     CrossRef
  • Association of Blood Fatty Acid Composition and Dietary Pattern with the Risk of Non-Alcoholic Fatty Liver Disease in Patients Who Underwent Cholecystectomy
    Poyoung Shim, Dongho Choi, Yongsoon Park
    Annals of Nutrition and Metabolism.2017; 70(4): 303.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
    Mehmet Sayiner, Aaron Koenig, Linda Henry, Zobair M. Younossi
    Clinics in Liver Disease.2016; 20(2): 205.     CrossRef
  • Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study
    Dhananjay Yadav, Eunhee Choi, Song Vogue Ahn, Sang Baek Koh, Ki-Chul Sung, Jang-Young Kim, Ji Hye Huh
    Medicine.2016; 95(31): e4447.     CrossRef
  • Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
    Hyunwoo Oh, Dae Won Jun, Waqar K Saeed, Mindie H Nguyen
    Clinical and Molecular Hepatology.2016; 22(3): 327.     CrossRef
  • Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE
    Josilda Ferreira Cruz, Mário Augusto Ferreira Cruz, José Machado Neto, Demetrius Silva de Santana, Cristiane Costa da Cunha Oliveira, Sônia Oliveira Lima
    Radiologia Brasileira.2016; 49(1): 1.     CrossRef
  • Development and Application of Low-Carbohydrates and Low-Simple Sugar Nutrition Education Materials for Non-Alcoholic Fatty Liver Disease Patients
    Yoo-Min An, Dae Won Jun, Seung Min Lee
    Clinical Nutrition Research.2015; 4(4): 250.     CrossRef
  • Association between Diabetes Mellitus and Fatty Liver Based on Ultrasonography Screening in the World's Highest Cholangiocarcinoma Incidence Region, Northeast Thailand
    Kavin Thinkhamrop, Narong Khuntikeo, Pichai Phonjitt, Nittaya Chamadol, Bandit Thinkhamrop, Malcolm Anthony Moore, Supannee Promthet
    Asian Pacific Journal of Cancer Prevention.2015; 16(9): 3931.     CrossRef
  • Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification
    Seng Chan You, Kwang Joon Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han
    Journal of Gastroenterology and Hepatology.2015; 30(10): 1536.     CrossRef
  • Prevalence of Nonalcoholic Fatty Liver Disease and Economy
    Jin-Zhou Zhu, Yi-Ning Dai, Yu-Ming Wang, Qin-Yi Zhou, Chao-Hui Yu, You-Ming Li
    Digestive Diseases and Sciences.2015; 60(11): 3194.     CrossRef
  • Use of Liver Magnetic Resonance Imaging After Standard Staging Abdominopelvic Computed Tomography to Evaluate Newly Diagnosed Colorectal Cancer Patients
    Kichang Han, Seong Ho Park, Kyung Won Kim, Hyoung Jung Kim, Seung Soo Lee, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, Yo-Sub Joo, Ah Young Kim, Hyun Kwon Ha
    Annals of Surgery.2015; 261(3): 480.     CrossRef
  • The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region
    Neeraj Bhala, Jacob George
    Current Hepatology Reports.2015; 14(2): 77.     CrossRef
  • 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics
    Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci, Guglielmo M Trovato
    EPMA Journal.2014;[Epub]     CrossRef
  • Clinical Correlation between Serum Cytokeratin-18 and Metabolic Parameters in Patients with Sonographic Non-alcoholic Fatty Liver Disease
    Dong Shin Kwak, Dae Won Jun, Yong Kyun Cho, Seung Min Lee, Se Hwan Lee, In Sub Jung, Sung Won Lee, Jae Keun Park, JungHoon Lee, Eun Young Lee, Min Rho, Kang Lok Lee, Jun Kwon Ko, Soon-Eung Park
    The Korean Journal of Gastroenterology.2014; 64(4): 206.     CrossRef
  • Epidemiology and Candidate Genes of Non-alcoholic Fatty Liver Disease
    Soo Lim
    The Journal of Korean Diabetes.2014; 15(2): 71.     CrossRef
  • 12,732 View
  • 106 Download
  • Crossref

Steatotic liver disease

Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
Hwa Mok Kim, Bum Soo Kim, Yong Kyun Cho, Byung Ik Kim, Chong Il Sohn, Woo Kyu Jeon, Hong Joo Kim, Dong Il Park, Jung Ho Park, Kwan Joong Joo, Chang Joon Kim, Yong Sung Kim, Woon Je Heo, Won Seok Choi
Clin Mol Hepatol 2013;19(3):258-265.
Published online September 30, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.3.258
Background/Aims

The red-blood-cell distribution width (RDW) is a newly recognized risk marker in patients with cardiovascular disease, but its role in nonalcoholic fatty liver disease (NAFLD) has not been well defined. The aim of the present study was to determine the association between RDW values and the level of fibrosis in NAFLD according to BARD and FIB-4 scores.

Methods

This study included 24,547 subjects who had been diagnosed with NAFLD based on abdominal ultrasonography and questionnaires about alcohol consumption. The degree of liver fibrosis was determined according to BARD and FIB-4 scores. The association between RDW values and the degree of fibrosis in NAFLD was analyzed retrospectively.

Results

After adjusting for age, hemoglobin level, mean corpuscular volume, history of hypertension, history of diabetes, and high-sensitivity C-reactive protein, the RDW values were 12.61±0.41% (mean±SD), 12.70±0.70%, 12.77±0.62%, 12.87±0.82%, and 13.25±0.90% for those with BARD scores of 0, 1, 2, 3, and 4, respectively, and 12.71±0.72%, 12.79±0.66%, and 13.23±1.52% for those with FIB-4 scores of <1.30, 1.31-2.66, and ≥2.67, respectively (P<0.05). The prevalence of advanced fibrosis (BARD score of 24 and FIB-4 score of ≥1.3) increased with the RDW [BARD score: 51.1% in quartile 1 (Q1) vs. 63.6% in Q4; FIB-4 score: 6.9% in Q1 vs. 10.5% in Q4; P<0.001]. After adjustments, the odds ratio of having advanced fibrosis for those in Q4 compared to Q1 were 1.76 (95%CI=1.55-2.00, P<0.001) relative to BARD score and 1.69 (95%CI=1.52-1.98, P<0.001) relative to FIB-4 score.

Conclusions

Elevated RDW is independently associated with advanced fibrosis in NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Letter to the Editor: Hematological traits in sodium-glucose cotransporter-2 efficacy: Mediators or confounders?
    Yuanhao Wei, Lanlan Chen, Kun Zhao
    Hepatology.2025; 81(3): E99.     CrossRef
  • Novel integrative models to predict the severity of inflammation and fibrosis in patients with drug-induced liver injury
    Yue Zhang, Chuan Lu, Jingying Xu, Qiqi Ma, Mei Han, Li Ying
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Prognostic significance of red cell distribution width to albumin ratio in ICU patients with Non-alcoholic fatty liver disease: a retrospective analysis
    Huan Yang, Libo Liang, Yan Liu, Xia Wang, Jinling Li, Xiao Du, He He
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling
    Serena Zampieri, Greta Petrella, Elisa Nagni, Laura Micheli, Francesca Maiorca, Ludovica Lombardi, Marilena Carbone, Annamaria Sabetta, Marzia Miglionico, Marin Pecani, Valeria Raparelli, Stefania Basili, Lucia Stefanini, Daniel Oscar Cicero, Adriano Pell
    Scientific Reports.2025;[Epub]     CrossRef
  • Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease
    Elżbieta Supruniuk, Kamil Grubczak, Anna Parfieniuk-Kowerda, Robert Flisiak, Marcin Moniuszko, Jerzy Jaroszewicz, Adrian Chabowski, Magdalena Świderska
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Hepatic Hydrothorax: A Contemporary Review for Pleural Physicians
    Yasmin Rahim, Raja Reddy
    Current Pulmonology Reports.2025;[Epub]     CrossRef
  • Association between body roundness index and risk of ultrasound-defined non-alcoholic fatty liver disease
    Enfa Zhao, Xiaolin Wen, Wenqian Qiu, Chaoxue Zhang
    Heliyon.2024; 10(1): e23429.     CrossRef
  • The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review
    Hunain Aslam, Fouzia Oza, Khalid Ahmed, Jonathan Kopel, Mark M. Aloysius, Aman Ali, Dushyant Singh Dahiya, Muhammad Aziz, Abhilash Perisetti, Hemant Goyal
    International Journal of Molecular Sciences.2023; 24(4): 3487.     CrossRef
  • An easy-to-use AIHF-nomogram to predict advanced liver fibrosis in patients with autoimmune hepatitis
    Zhiyi Zhang, Jian Wang, Huali Wang, Yuanwang Qiu, Li Zhu, Jiacheng Liu, Yun Chen, Yiguang Li, Yilin Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Xiaomin Yan, Yali Xiong, Yongfeng Yang, Qun Zhang, Jie Li, Chuanwu Zhu, Chao Wu, Rui Huang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Evaluation of Hematological Biomarkers in Childhood Metabolic Dysfunction Associated Steatotic Liver Disease
    Meltem GÜMÜŞ, Alaaddin YORULMAZ, Hakan CANDAN, Mehmet ÖZTÜRK, Fuat BUĞRUL, Halil Haldun EMİROĞLU
    Journal of Contemporary Medicine.2023; 13(5): 1024.     CrossRef
  • Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study
    Szymon Suwała, Aleksandra Białczyk, Kinga Koperska, Alicja Rajewska, Magdalena Krintus, Roman Junik
    Journal of Clinical Medicine.2023; 12(24): 7760.     CrossRef
  • Association of Hematological Parameters (Mean Platelet Volume and Red Cell Distribution Width) with Nonalcoholic Fatty Liver Disease
    Sonika Verma, Manish Verma, Sunny Khari
    APIK Journal of Internal Medicine.2023; 11(1): 37.     CrossRef
  • The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome
    Atakan Turgutkaya, Nesim Akın, Gökhan Sargın, Zahit Bolaman, İrfan Yavaşoğlu
    Hematology, Transfusion and Cell Therapy.2022; 44(3): 332.     CrossRef
  • Brewed chicory leaf consumption has unexpected side effects along beneficial effects on liver enzymes in non-alcoholic fatty liver disease patients
    Samira Faraji, Mohammad Reza Mohammad Hosseini Azar, Mohammad Alizadeh
    Journal of Herbal Medicine.2022; 34: 100572.     CrossRef
  • The fibrosis‐4 score is associated with long‐term mortality in different phenotypes of acute heart failure
    Chih‐Hsueh Tseng, Wei‐Min Huang, Wen‐Chung Yu, Hao‐Min Cheng, Hao‐Chih Chang, Pai‐Feng Hsu, Chern‐En Chiang, Chen‐Huan Chen, Shih‐Hsien Sung
    European Journal of Clinical Investigation.2022;[Epub]     CrossRef
  • Increased red cell distribution width predicts severity of drug-induced liver injury: a retrospective study
    Xu Li, Hongqin Xu, Pujun Gao
    Scientific Reports.2021;[Epub]     CrossRef
  • Accuracy of gamma-glutamyl transpeptidase-to-platelet ratio (GPR), red cell distribution width (RDW), aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis-4 index (FIB4) compared with liver biopsy in patients with drug-induced liver
    Minjie Wan, Hongqin Xu, Dezhao Li, Le Wang, Xu Li
    Medicine.2021; 100(6): e24723.     CrossRef
  • Nonlinear Relationship Between Macrocytic Anemia and Decompensated Hepatitis B Virus Associated Cirrhosis: A Population-Based Cross-Sectional Study
    Tian-Yu Zhao, Qing-Wei Cong, Fang Liu, Li-Ying Yao, Ying Zhu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Red blood cell distribution width: A promising index for evaluating the severity and long-term prognosis of hepatitis B virus–related diseases
    Jian Wang, Rui Huang, Xiaomin Yan, Ming Li, Yuxin Chen, Juan Xia, Yong Liu, Bei Jia, Li Zhu, Zhaoping Zhang, Chuanwu Zhu, Chao Wu
    Digestive and Liver Disease.2020; 52(4): 440.     CrossRef
  • Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis
    Huali Wang, Jian Wang, Juan Xia, Xiaomin Yan, Yanhong Feng, Lin Li, Jun Chen, Duxian Liu, Weimao Ding, Yongfeng Yang, Rui Huang, Chao Wu
    Medicine.2020; 99(34): e21408.     CrossRef
  • Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial
    Helda Tutunchi, Fatemeh Naeini, Maryam Saghafi-Asl, Nazila Farrin, Alireza Monshikarimi, Alireza Ostadrahimi
    Health Promotion Perspectives.2020; 10(4): 373.     CrossRef
  • Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease
    Wen-Jie Zhou, Jing Yang, Ge Zhang, Zheng-Qiang Hu, Yong-Mei Jiang, Fan Yu
    Medicine.2019; 98(30): e16565.     CrossRef
  • Red cell distribution width to platelet ratio for liver fibrosis: a systematic review and meta-analysis of diagnostic accuracy
    Gerasimos P. Milas, Vasilios Karageorgiou, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2019; 13(9): 877.     CrossRef
  • Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis
    Huali Wang, Jian Wang, Rui Huang, Juan Xia, Lingyun Zuo, Xiaomin Yan, Yongfeng Yang, Chao Wu
    European Journal of Gastroenterology & Hepatology.2019; 31(12): 1527.     CrossRef
  • Macrocytic anemia is associated with the severity of liver impairment in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective cross-sectional study
    Jian Yang, Bin Yan, Lihong Yang, Huimin Li, Yajuan Fan, Feng Zhu, Jie Zheng, Xiancang Ma
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • The role of red cell distribution width as a noninvasive index for predicting liver cell failure and portal hypertension in cirrhotic patients
    Howaida A. Nafady, Tarek A. Hassan, Lobna A. Ahmed, Marina A. Waheeb
    The Egyptian Journal of Internal Medicine.2018; 30(4): 255.     CrossRef
  • Preliver transplant red cell distribution width predicts postliver transplant mortality
    M. Thure Caire, Ambuj Kumar, R. Todd Stravitz, Nyingi Kemmer
    Clinical Transplantation.2017;[Epub]     CrossRef
  • Red cell distribution width as a significant indicator of medication and prognosis in type 2 diabetic patients
    Xiao-fen Xiong, Yuan Yang, Xianghui Chen, Xuejing Zhu, Chun Hu, Yachun Han, Li Zhao, Fuyou Liu, Lin Sun
    Scientific Reports.2017;[Epub]     CrossRef
  • Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Valentina Giorgio, Antonella Mosca, Arianna Alterio, Anna Alisi, Antonio Grieco, Valerio Nobili, Luca Miele
    Journal of Pediatric Gastroenterology and Nutrition.2017; 65(2): 150.     CrossRef
  • Prognostic significance of red blood cell distribution width in gastrointestinal disorders
    Hemant Goyal, Giuseppe Lippi, Altin Gjymishka, Bijo John, Rajiv Chhabra, Elizabeth May
    World Journal of Gastroenterology.2017; 23(27): 4879.     CrossRef
  • Diabetes and red blood cell parameters
    Jaman MS
    Annals of Clinical Endocrinology and Metabolism.2017; 2(1): 001.     CrossRef
  • Red Blood Cell Distribution Width Levels Correlate With Liver Fibrosis and Inflammation
    Wen-Shen Xu, Xiao-Ming Qiu, Qi-shui Ou, Can Liu, Jin-Piao Lin, Hui-Juan Chen, Sheng Lin, Wen-Hua Wang, Shou-Rong Lin, Jing Chen
    Medicine.2015; 94(10): e612.     CrossRef
  • Reduced Red Blood Cell Count Predicts Poor Survival After Surgery in Patients With Primary Liver Cancer
    Xiaomeng Xie, Mingjie Yao, Xiangmei Chen, Weiquan Lu, Quanjun Lv, Kaijuan Wang, Ling Zhang, Fengmin Lu
    Medicine.2015; 94(8): e577.     CrossRef
  • Red blood cell distribution width: A simple parameter with multiple clinical applications
    Gian Luca Salvagno, Fabian Sanchis-Gomar, Alessandra Picanza, Giuseppe Lippi
    Critical Reviews in Clinical Laboratory Sciences.2015; 52(2): 86.     CrossRef
  • Utility of RDW in Prediction of Strangulation in Emergency Setting Hernias
    Okan Akturk, Baris Dogu Yildiz, Melih Karabeyoglu, Isıl Karabeyoglu
    International Surgery.2015; 100(9-10): 1262.     CrossRef
  • Red cell distribution width as a potential index to assess the severity of hepatitis B virus‐related liver diseases
    Rui Huang, Chenchen Yang, Kangkang Wu, Shufeng Cao, Yong Liu, Ran Su, Yali Xiong, Aijun Huang, Chao Wu
    Hepatology Research.2014;[Epub]     CrossRef
  • Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients
    Jinmei Yao, Ying Zhao, Juanwen Zhang, Yani Hong, Huanle Lu, Jianping Wu
    Lipids in Health and Disease.2014;[Epub]     CrossRef
  • Assessment of the relationship between red cell distribution width and fragmented QRS in patients with non-ST elevated acute coronary syndrome
    Mustafa Yılmaz
    Medical Science Monitor.2014; 20: 413.     CrossRef
  • Red cell distribution width and nonalcoholic steatohepatitis
    Yasemin Gulcan Kurt, Tuncer Cayci, Fevzi Nuri Aydin, Mehmet Agilli
    World Journal of Gastroenterology.2014; 20(43): 16387.     CrossRef
  • Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD
    Wonseok Kang, Seung Up Kim
    Clinical and Molecular Hepatology.2013; 19(3): 255.     CrossRef
  • 13,220 View
  • 114 Download
  • Crossref

Viral hepatitis

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
Dae Won Jun, Byung Ik Kim, Yong Kyun Cho, Hong Ju Kim, Young Oh Kwon, Soo Young Park, Sang Young Han, Yang Hyun Baek, Yong Jin Jung, Hwi Young Kim, Won Kim, Jeong Heo, Hyun Young Woo, Seong Gyu Hwang, Kyu Sung Rim, Jong Young Choi, Si Hyun Bae, Young Sang Lee, Young Suck Lim, Jae Youn Cheong, Sung Won Cho, Byung Seok Lee, Seok Hyun Kim, Joo Hyun Sohn, Tae Yeob Kim, Yong Han Paik, Ja Kyung Kim, Kwan Sik Lee
Clin Mol Hepatol 2013;19(2):165-172.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.165
Background/Aims

Carnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.

Methods

130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.

Results

Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.

Conclusions

ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
    Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
    Arabian Journal of Chemistry.2023; 16(8): 105013.     CrossRef
  • Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
    Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jae Young Jang, Dong Joon Kim, Eun‐Sook Park, So‐Young Jin, Kyun‐Hwan Kim
    Journal of Gastroenterology and Hepatology.2022; 37(2): 378.     CrossRef
  • Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center–Related Immune Cells
    Shuqin Gu, Weibin Wang, Guofu Ye, Chengcong Chen, Yang Zhou, Ling Guo, Shihong Zhong, Xiaoyi Li, Xin Fu, Chunhua Wen, Libo Tang, Jian Sun, Jinlin Hou, Yongyin Li
    The Journal of Infectious Diseases.2022; 225(11): 1955.     CrossRef
  • Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
    Eileen L. Yoon, Sang Bong Ahn, Dae Won Jun, Yong Kyun Cho, Do Seon Song, Jae Yoon Jeong, Hee Yeon Kim, Young Kul Jung, Myeong Jun Song, Sung Eun Kim, Hyoung Su Kim, Soung Won Jeong, Sang Gyune Kim, Tae Hee Lee
    The Korean Journal of Internal Medicine.2022; 37(4): 757.     CrossRef
  • Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials
    Hyunwoo Oh, Chan Hyuk Park, Dae Won Jun
    Journal of Personalized Medicine.2022; 12(7): 1053.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
    Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Journal of Personalized Medicine.2022; 12(12): 1970.     CrossRef
  • Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
    Na Li, Hui Zhao
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
    Shuqin Gu, Xin Fu, Guofu Ye, Chengcong Chen, Xiaoyi Li, Shihong Zhong, Libo Tang, Haitao Chen, Deke Jiang, Jinlin Hou, Yongyin Li
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway
    Jung-Hee Hong, Moon-Kyu Lee
    Diabetes & Metabolism Journal.2021; 45(6): 933.     CrossRef
  • Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials
    Farzaneh Pirmadah, Nahid Ramezani-Jolfaie, Mohammad Mohammadi, Nasir Talenezhad, Cain C. T. Clark, Amin Salehi-Abargouei
    European Journal of Nutrition.2020; 59(5): 1767.     CrossRef
  • The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice
    Rania A. Abdel-Emam, Esraa A. Ahmed, Marwa F. Ali
    Comparative Clinical Pathology.2020; 29(1): 213.     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
    Esmaeil Yousefi Rad, Elham Eslampour, Ebrahim Falahi, Mahnaz Mardani, Azita Hekmatdoost, Omid Asbaghi, Somayeh Saboori
    Indian Journal of Gastroenterology.2019; 38(6): 470.     CrossRef
  • L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
    Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi,
    Hepatology Communications.2018; 2(8): 910.     CrossRef
  • Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature
    Rachael R. Schulte, Manasi V. Madiwale, Allyson Flower, Jessica Hochberg, Michael J. Burke, Jennifer L. McNeer, Adam DuVall, Archie Bleyer
    Leukemia & Lymphoma.2018; 59(10): 2360.     CrossRef
  • Anti-adipogenic and antiviral effects ofl-carnitine on hepatitis C virus infection
    Yoko Tsukuda, Goki Suda, Seiji Tsunematsu, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Megumi Kimura, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Naoya Sakamo
    Journal of Medical Virology.2017; 89(5): 857.     CrossRef
  • Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition
    Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
    European Journal of Pharmaceutical Sciences.2017; 106: 313.     CrossRef
  • A Case of Therapeutic Laser for Suggested Drug Induced Liver Injury Patient during Treatment of Korean Medicine
    Kyeong-Tae Lim, Byung-Cheul Shin, Eui-Hyoung Hwang, In Heo, Byung-Jun Kim, Kwang-Ho Heo
    Journal of Korean Medicine Rehabilitation.2016; 26(3): 183.     CrossRef
  • Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
    Zhongqi Dong, Sean Ekins, James E. Polli
    European Journal of Pharmaceutical Sciences.2015; 66: 1.     CrossRef
  • Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
    Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
    The Korean Journal of Gastroenterology.2014; 64(1): 31.     CrossRef
  • 13,837 View
  • 177 Download
  • Crossref

Steatotic liver disease

The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults
Deok Yun Ju, Young Gil Choe, Yong Kyun Cho, Dong Suk Shin, Su Hyeon Yoo, Seo Hyoung Yim, Ji Yong Lee, Jung Ho Park, Hong Joo Kim, Dong Il Park, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol 2013;19(2):140-147.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.140
Background/Aims

Waist circumference (WC) is a risk factor for metabolic syndrome and is related to insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to determine the association between WC and IR and NAFLD in apparently healthy Korean adults.

Methods

The volunteers included in this cross-sectional study comprised 9,159 adults (5,052 men, 4,107 women) who participated in a comprehensive health checkup program. IR was evaluated by the homeostasis model assessment of IR (HOMA-IR) and was considered to be present when the HOMA-IR score was >2. NAFLD was evaluated by ultrasound examination. Elevated alanine aminotransferase (ALT) was defined as >40 IU/L in men and >35 IU/L in women. Logistic regression was performed to determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) for NAFLD, IR, and ALT according to categorized levels of WC.

Results

NAFLD was found in 2,553 (27.9%) of the participants (82.6% men, 17.4% women), while IR and elevated ALT were found in 17.2% (68.1% men, 31.9% women) and 10% (83% men, 17% women), respectively. After adjusting for confounding factors, the prevalence of NAFLD, IR, and elevated ALT was significantly associated with increases in WC quartile: highest quartile for NAFLD in men, OR=15.539, 95% CI=12.687-19.033; highest quartile for NAFLD in women, OR=48.732, 95% CI=23.918-99.288 (P<0.001); and highest quartile for IR in men, OR=17.576, 95% CI=13.283-23.255; highest quartile for IR in women, OR=11.078, 95% CI=7.813-15.708 (P<0.001); highest quartile for elevated ALT in men, OR=7.952, 95% CI=6.046-10.459; and highest quartile for elevated ALT in women, OR=8.487, 95% CI=4.679-15.395 (P<0.001).

Conclusions

WC contributes to IR and NAFLD in apparently healthy Korean adults, and thus may be an important factor in the development of IR and NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between TyG-related parameters and NAFLD risk in Japanese non-obese population
    Xiuli Wang, Jie Liu, Ke Yu, Zhenhua Huang, Hanxiong Liu, Xiang Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease
    Hanaa Badran, Maha Elsabaawy, Mai Magdy, Hazem Omar, Olfat Hendy, Eman Awaad, Maymona Abd El-Wahed Al-Khalifa, Mai Abozeid
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Study of association and diagnostic utility of novel anthropometric and lipid indices for nonalcoholic fatty liver disease: A hospital-based study
    Anand K. Pyati, Sakthivadivel Varatharajan, Abhishek Arora, Vaman Kulkarni, Aparna Varma Bhongir, Sangeetha Sampath, Gomathi Ramaswamy, Madhu Latha Karra, Priyanka Das, Pawan Pagaku
    Journal of Family Medicine and Primary Care.2025; 14(6): 2365.     CrossRef
  • Global prevalence of insulin resistance in the adult population: a systematic review and meta-analysis
    Jhosmer Ballena-Caicedo, Fiorella E. Zuzunaga-Montoya, Joan A. Loayza-Castro, Juan Carlos Bustamante-Rodríguez, Luisa Erika Milagros Vásquez Romero, Rafael Tapia-Limonchi, Carmen Inés Gutierrez De Carrillo, Víctor Juan Vera-Ponce
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Exploring The Impact of Dietary and Metabolic Risk Factors on Non-Alcoholic Fatty Liver Disease (NAFLD) : A Cross-Sectional Study
    İzel Aycan Orakçı, İlyas Tuncer, Fatma Esra Güneş
    Turkish Journal of Health Science and Life.2025; 8(2): 29.     CrossRef
  • Garlic ( Allium sativum L. ) in diabetes and its complications: Recent advances in mechanisms of action
    Yayi Jiang, Rensong Yue, Guojie Liu, Jun Liu, Bo Peng, Maoyi Yang, Lianxue Zhao, Zihan Li
    Critical Reviews in Food Science and Nutrition.2024; 64(16): 5290.     CrossRef
  • Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan
    Seogsong Jeong, Sun Jae Park, Seong Kyun Na, Sang Min Park, Byung-Cheol Song, Yun Hwan Oh
    Hepatobiliary & Pancreatic Diseases International.2024; 23(4): 353.     CrossRef
  • Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study
    Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa
    PLOS ONE.2024; 19(5): e0303333.     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Waist to height ratio in nonalcoholic fatty liver disease – Systematic review and meta-analysis
    Abdulrahman Ismaiel, Blal El Hosiny, Mohamed Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Cristina Sorina Catana, Dan L. Dumitrascu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102160.     CrossRef
  • Is There any Need for the Early Detection of Non-alcoholic Fatty Liver Disease in Children with Type 1 Diabetes Mellitus?
    Soodeh Salehi, Sanaz Mehrpour, Shahin Koohmanaee, Shohreh Maleknejad, Mohammad Ali Esfandiari, Saman Maroufizadeh, Setila Dalili, Afagh Hassanzadeh Rad
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults
    Meiling Li, Weiping Zhang, Xiude Li, Shaoxian Liang, Yaozong Zhang, Yufeng Mo, Songxian Rao, Honghua Zhang, Yong Huang, Yu Zhu, Zhuang Zhang, Wanshui Yang
    Nutrients.2023; 15(13): 2856.     CrossRef
  • Neck Circumference as a Predictor of Insulin Resistance in People with Non-alcoholic Fatty Liver Disease
    Da-Hye Son, Jee Hye Han, Jun-Hyuk Lee
    Journal of Obesity & Metabolic Syndrome.2023; 32(3): 214.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis
    Katherine J.P. Schwenger, Alexander Kiu, Maryam AlAli, Amnah Alhanaee, Sandra E. Fischer, Johane P. Allard
    Nutrition.2022; 93: 111491.     CrossRef
  • The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease
    Maobin Kuang, Guotai Sheng, Chong Hu, Song Lu, Nan Peng, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION?
    Bárbara Ferreira de Mello BARRETO, Giovana Rita PUNARO, Maria Cristina ELIAS, Edison Roberto PARISE
    Arquivos de Gastroenterologia.2022; 59(3): 402.     CrossRef
  • Identify Functional lncRNAs in Nonalcoholic Fatty Liver Disease by Constructing a ceRNA Network
    Wei Xue, Jia Zhang, Yali Zhu, Wenxiang Huang
    ACS Omega.2022; 7(26): 22522.     CrossRef
  • Anthropometric clinical indicators of visceral adiposity as predictors of nonalcoholic fatty liver disease
    Naiade Silveira Almeida, Raquel Rocha, Carla Daltro, Claudineia Almeida de Souza, Rafael Leiróz Pereira Duarte Silva, Manoel Alfredo Curvelo Sarno, Helma Pinchemel Cotrim
    Revista da Associação Médica Brasileira.2021; 67(11): 1544.     CrossRef
  • Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
    Jinwei Cai, Cuiting Lin, Shuiqing Lai, Yingshan Liu, Min Liang, Yingfen Qin, Xinghuan Liang, Aihua Tan, Yong Gao, Zheng Lu, Chunlei Wu, Shengzhu Huang, Xiaobo Yang, Haiying Zhang, Jian Kuang, Zengnan Mo
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Comparison of Body Mass Index and Fat Indices in Predicting the Severity of Nonalcoholic Fatty Liver Disease Among Children Who Are Overweight and Obese
    Hsun-Chin Chao, Hsin-Yeh Lin
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
    Pegah Golabi, James M. Paik, Tamoore Arshad, Youssef Younossi, Alita Mishra, Zobair M. Younossi
    Hepatology Communications.2020; 4(8): 1136.     CrossRef
  • Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review
    Shagufta Akhtar, Azhar Khan
    Advanced Journal of Graduate Research.2020; 9(1): 46.     CrossRef
  • Clinical, Anthropometric, Biochemical and Histological Character of Nonalcoholic Fatty Liver Disease Without Insulin Resistance
    Shahinul Alam, Kamrul Anam, Saiful Islam, Golam Mustafa, Ayub Al Mamun, Nooruddin Ahmad
    Journal of Clinical and Experimental Hepatology.2019; 9(2): 176.     CrossRef
  • Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity
    Antônio Sérgio Barcala Jorge, João Marcus Oliveira Andrade, Alanna Fernandes Paraíso, Gislaine Candida Batista Jorge, Christine Mendes Silveira, Ludmilla Regina de Souza, Erivelton Pereira Santos, André Luiz Sena Guimaraes, Sérgio Henrique Sousa Santos, A
    Obesity Research & Clinical Practice.2018; 12(1): 1.     CrossRef
  • Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review
    Naiade Silveira Almeida, Raquel Rocha, Helma Pinchemel Cotrim, Carla Daltro
    World Journal of Hepatology.2018; 10(10): 695.     CrossRef
  • Circunferência da cintura como marcador para triagem de doença hepática gordurosa não alcoólica em adolescentes obesos
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho‐Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria.2016; 34(1): 47.     CrossRef
  • Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho-Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria (English Edition).2016; 34(1): 47.     CrossRef
  • Relationship of Colorectal Polyps and Fatty Liver Disease Diagnosed by Ultrasonography
    Hye-Nam Lee, Cheong-Hwan Lim, Hong-Ryang Jung
    Journal of Digital Convergence.2014; 12(3): 345.     CrossRef
  • Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
    Xing-Chun Wang
    World Journal of Gastroenterology.2014; 20(40): 14821.     CrossRef
  • 11,059 View
  • 79 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data
Moon Young Kim, Soon Ho Um, Soon Koo Baik, Yeon Seok Seo, Soo Young Park, Jung Il Lee, Jin Woo Lee, Gab Jin Cheon, Joo Hyun Sohn, Tae Yeob Kim, Young Suk Lim, Tae Hyo Kim, Tae Hee Lee, Sung Jae Park, Seung Ha Park, Jin Dong Kim, Sang Young Han, Chang Soo Choi, Eun Young Cho, Dong Joon Kim, Jae Seok Hwang, Byoung Kuk Jang, June Sung Lee, Sang Gyune Kim, Young Seok Kim, So Young Kwon, Won Hyeok Choe, Chang Hyeong Lee, Byung Seok Kim, Jae Young Jang, Soung Won Jeong, Byung Ho Kim, Jae Jun Shim, Yong Kyun Cho, Moon Soo Koh, Hyun Woong Lee
Korean J Hepatol 2013;19(1):36-44.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.36
Background/Aims

While gastric variceal bleeding (GVB) is not as prevalent as esophageal variceal bleeding, it is reportedly more serious, with high failure rates of the initial hemostasis (>30%), and has a worse prognosis than esophageal variceal bleeding. However, there is limited information regarding hemostasis and the prognosis for GVB. The aim of this study was to determine retrospectively the clinical outcomes of GVB in a multicenter study in Korea.

Methods

The data of 1,308 episodes of GVB (males:females=1062:246, age=55.0±11.0 years, mean±SD) were collected from 24 referral hospital centers in South Korea between March 2003 and December 2008. The rates of initial hemostasis failure, rebleeding, and mortality within 5 days and 6 weeks of the index bleed were evaluated.

Results

The initial hemostasis failed in 6.1% of the patients, and this was associated with the Child-Pugh score [odds ratio (OR)=1.619; P<0.001] and the treatment modality: endoscopic variceal ligation, endoscopic variceal obturation, and balloon-occluded retrograde transvenous obliteration vs. endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, and balloon tamponade (OR=0.221, P<0.001). Rebleeding developed in 11.5% of the patients, and was significantly associated with Child-Pugh score (OR=1.159, P<0.001) and treatment modality (OR=0.619, P=0.026). The GVB-associated mortality was 10.3%; mortality in these cases was associated with Child-Pugh score (OR=1.795, P<0.001) and the treatment modality for the initial hemostasis (OR=0.467, P=0.001).

Conclusions

The clinical outcome for GVB was better for the present cohort than in previous reports. Initial hemostasis failure, rebleeding, and mortality due to GVB were universally associated with the severity of liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Treatment of Gastric Varices
    Thomas J. Wang, Marvin Ryou
    Current Hepatology Reports.2024; 23(2): 287.     CrossRef
  • Endoscopic Treatment and Prevention of Acute Variceal Hemorrhage
    Youngdae Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(1): 5.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration: A Modified Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Varices
    Dong Il Gwon, Hyun-Ki Yoon
    Digestive Disease Interventions.2024; 08(03): 183.     CrossRef
  • Coil- and Plug-Assisted Transvenous Retrograde Obliteration (CARTO/PARTO) in the Treatment of Gastric Varices: A European Single Centre Experience
    Giuseppe Pelle, Flavio Andresciani, Massimo Messina, Silvia Nardelli, Lorenzo Ridola, Ermanno Notarianni, Adelchi Saltarelli, Stefania Gioia, Alessandro Tanzilli, Cesare Ambrogi
    Gastrointestinal Disorders.2024; 6(3): 742.     CrossRef
  • Ендоскопічне лікування кровотеч із варикозно розширених вен шлунка
    S.M. Chooklin, S.S. Chuklin, Ya.R. Dutka
    EMERGENCY MEDICINE.2022; 18(5): 44.     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • Comparison of the Effects of TIPS versus BRTO on Bleeding Gastric Varices: A Meta-Analysis
    Zi Wen Wang, Jin Chao Liu, Fang Zhao, Wen Guang Zhang, Xu Hua Duan, Peng Fei Chen, Si Fu Yang, Hong Wei Li, Fu Wen Chen, Hong Sheng Shi, Jian Zhuang Ren
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Treatment of Gastric Varices Because of Portal Hypertension
    Swathi Paleti, Venkat Nutalapati, Jihan Fathallah, Sravan Jeepalyam, Tarun Rustagi
    Journal of Clinical Gastroenterology.2020; 54(7): 655.     CrossRef
  • Endoscopic Therapy and Radiologic Intervention of Acute Gastroesophageal Variceal Bleeding
    Jeong Eun Song, Byung Seok Kim
    Clinical Endoscopy.2019; 52(5): 407.     CrossRef
  • Detection of fundic varices obturation by endoscopic ultrasound versus multidetector computed tomography
    Amr Elrabat, Salah El-Gamal, Mohammad M. Kashwaa, Mohamed M. El-Rakhawy
    The Egyptian Journal of Internal Medicine.2019; 31(4): 487.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: The Role of Intra-Procedural Cone-Beam Computed Tomography
    Dong Il Gwon, Gi-Young Ko, Young Baek Kwon, Hyun-Ki Yoon, Kyu-Bo Sung
    Korean Journal of Radiology.2018; 19(2): 223.     CrossRef
  • Prevention and management of gastroesophageal varices
    Yeon Seok Seo
    Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
  • Innovative Technique for Endoscopic Placement of Sengstaken-Blakemore Tube
    Arleen M. Ortiz, Cesar J. Garcia, Mohamed O. Othman, Marc J. Zuckerman
    Southern Medical Journal.2018; 111(5): 307.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Geunwu Gimm, Young Chang, Hyo-Cheol Kim, Aesun Shin, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2018; 12(6): 704.     CrossRef
  • Management of different types of gastric varices with band ligation: a 3-year experience
    Waseem M. Seleem, Amr S. Hanafy
    European Journal of Gastroenterology & Hepatology.2017; 29(8): 968.     CrossRef
  • Balloon‐occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: A meta‐analysis
    Yun‐Bing Wang, Jian‐Ying Zhang, Jian‐Ping Gong, Fan Zhang, Yong Zhao
    Journal of Gastroenterology and Hepatology.2016; 31(4): 727.     CrossRef
  • Usefulness of intra-procedural cone-beam computed tomography in modified balloon-occluded retrograde transvenous obliteration of gastric varices
    Edward Wolfgang Lee, Naomi So, Ryan Chapman, Justin P McWilliams, Christopher T Loh, Ronald W Busuttil, Stephen T Kee
    World Journal of Radiology.2016; 8(4): 390.     CrossRef
  • Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding
    Weiguang Qiao, Yutang Ren, Yang Bai, Side Liu, Qiang Zhang, Fachao Zhi
    Medicine.2015; 94(41): e1725.     CrossRef
  • Novel Use of Glidescope Indirect Laryngoscopy for Insertion of a Minnesota Tube for Variceal Bleeding
    Adam B. Schlichting, Jayna M. Gardner-Gray, Gina Hurst
    The Journal of Emergency Medicine.2015; 49(1): 40.     CrossRef
  • Re-Bleeding in Patients With Cirrhosis: Evaluation of Esophageal and Gastric Variceal Bleeding and Their Relationship With a Model for the End-Stage Liver Disease (MELD) Score and Child-Pugh Score
    Mohsen Ebrahimi, Hamidreza Reihani, Mohammadreza Sheikhian, Ehsan Bolvardi, Masumeh Pashayi, Elham Pishbin
    Razavi International Journal of Medicine.2014;[Epub]     CrossRef
  • Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
    Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, Ji Hoon Na, Hyun Sik Kim, Hyoun A Kim, Hye Won Kang, Soon Koo Baik, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Moon Young Kim
    Clinical and Molecular Hepatology.2014; 20(4): 376.     CrossRef
  • The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding
    Moon Han Choi, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Yu Ri Seo, Min Jin Kim, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2013; 19(3): 280.     CrossRef
  • 13,123 View
  • 86 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study
Se Young Jang, Go Heun Kim, Soo Young Park, Chang Min Cho, Won Young Tak, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Jae Myeong Lee, Sang Gyune Kim, Dae Yong Kim, Young Seok Kim, Se-Ok Lee, Yang Won Min, Joon Hyeok Lee, Seung Woon Paik, Byung Chul Yoo, Jae Wan Lim, Hong Joo Kim, Yong Kyun Cho, Joo Hyun Sohn, Jae Yoon Jeong, Yu Hwa Lee, Tae Yeob Kim, Young Oh Kweon
Korean J Hepatol 2012;18(4):368-374.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.368
Background/Aims

This study evaluated the clinical outcomes of balloon-occluded retrograde transvenous obliteration (BRTO) for the treatment of hemorrhage from gastric varices (GV) in Korean patients with liver cirrhosis (LC).

Methods

We retrospectively analyzed data from 183 LC patients who underwent BRTO for GV bleeding in 6 university-based hospitals between January 2001 and December 2010.

Results

Of the 183 enrolled patients, 49 patients had Child-Pugh (CP) class A LC, 105 had CP class B, and 30 had CP class C at the time of BRTO. BRTO was successfully performed in 177 patients (96.7%). Procedure-related complications (e.g., pulmonary thromboembolism and renal infarction) occurred in eight patients (4.4%). Among 151 patients who underwent follow-up examinations of GV, 79 patients (52.3%) achieved eradication of GV, and 110 patients (72.8%) exhibited marked shrinkage of the treated GV to grade 0 or I. Meanwhile, new-appearance or aggravation of esophageal varices (EV) occurred in 54 out of 136 patients who underwent follow-up endoscopy (41.2%). During the 36.0±29.2 months (mean±SD) of follow-up, 39 patients rebled (hemorrhage from GV in 7, EV in 18, nonvariceal origin in 4, and unknown in 10 patients). The estimated 3-year rebleeding-free rate was 74.8%, and multivariate analysis showed that CP class C was associated with rebleeding (odds ratio, 2.404; 95% confidence-interval, 1.013-5.704; P=0.047).

Conclusions

BRTO can be performed safely and effectively for the treatment of GV bleeding. However, aggravation of EV or bleeding from EV is not uncommon after BRTO; thus, periodic endoscopy to follow-up of EV with or without prophylactic treatment might be necessary in LC patients undergoing BRTO.

Citations

Citations to this article as recorded by  Crossref logo
  • Coil or plug-assisted retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study
    Edward Wolfgang Lee, Sammy Saab, Navid Eghbalieh, Peng-Xu Ding, Ung Bae Jeon, Joon Young Ohm, Ronnie C. Chen, Man-Deuk Kim, Kichang Han, Dong Jae Shim, Jong Soo Shin, Anirudh Mirakhur, Chien-An Liu, Jonathan Park, Frank Hao, Man Wong, Antonio Moreno, Jasl
    Hepatology.2025; 82(6): 1498.     CrossRef
  • Prognostic Impact of C-reactive Protein-Albumin-Lymphocyte Index in Patients Who Underwent Splenectomy and Devascularization for Gastric Varices Caused by Portal Hypertension
    Ko Oshita, Tsuyoshi Kobayashi, Naruhiko Honmyo, Seiichi Shimizu, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Hideki Ohdan
    Cureus.2025;[Epub]     CrossRef
  • Long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for refractory hepatic encephalopathy
    Dong II Gwon, Gun Ha Kim, Hee Ho Chu, Jihoon Kim, Byoung Soo Im, Eunbyeol Ko, Jeongyeon Kim, Jin Hyoung Kim, Gi-Young Ko, Hyun-Ki Yoon
    European Radiology.2025; 36(1): 719.     CrossRef
  • Clinical Outcomes and Their Determinants in Patients With Gastric Variceal Bleed Undergoing Endoscopic Cyanoacrylate Injection: An Observational Study
    Dharanesh Daneti, Kuppusamy Senthamizhselvan, Mamidala R.V. Chandra, Pazhanivel Mohan, Vikram Kate
    Journal of Clinical and Experimental Hepatology.2024; 14(3): 101315.     CrossRef
  • A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization
    Won‐Mook Choi, Seo Yeon Yoo, Jong‐In Chang, Seungbong Han, Young Seok Kim, Dong Hyun Sinn, Sang Hyun Choi, Dong Il Gwon, Young‐Suk Lim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1629.     CrossRef
  • Long-Term Prognosis and Related Factors in Patients with Cirrhosis Treated with Balloon-Occluded Retrograde Transvenous Obliteration
    Yamato Tamura, Yoshinari Asaoka, Akihito Takeuchi, Kosuke Matsumoto, Ryo Miura, Koichiro Abe, Toshihiko Arizumi, Masayoshi Yamamoto, Shinya Kodashima, Hiroshi Kondo, Takatsugu Yamamoto, Atsushi Tanaka
    Digestive Diseases.2023; 41(5): 789.     CrossRef
  • Clinical outcomes related to portal pressures before and after embolization of large portosystemic shunts in cirrhosis
    Sasidharan Rajesh, Cyriac Abby Philips, Rizwan Ahamed, Shobhit Singh, Jinsha K Abduljaleel, Ajit Tharakan, Philip Augustine
    SAGE Open Medicine.2023;[Epub]     CrossRef
  • Variceal Hemorrhage: Decompression, Obliteration, or Both?
    Benjamin J. McCafferty, Husamedin El Khudari, Aliaksei Salei, Andrew J. Gunn
    Digestive Disease Interventions.2022; 06(02): 094.     CrossRef
  • Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients
    Taku Mizutani, Kazushige Nirei, Tatsuo Kanda, Masayuki Honda, Tomotaka Ishii, Shuhei Arima, Yoichiro Yamana, Naoki Matsumoto, Shunichi Matsuoka, Mitsuhiko Moriyama
    Medicina.2022; 58(2): 205.     CrossRef
  • Progress in Endoscopic and Interventional Treatment of Esophagogastric Variceal Bleeding
    Bin Liu, Gang Li, Simin Li
    Disease Markers.2022; 2022: 1.     CrossRef
  • Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis
    Han Ah Lee, Jungwon Kwak, Sung Bum Cho, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Seung Up Kim, Hyonggin An, Hyung Joon Yim, Jong Eun Yeon, Yeon Seok Seo
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Comprehensive treatment of patients with gastric variceal bleeding
    S.M. Chooklin, S.S. Chuklin
    EMERGENCY MEDICINE.2022; 18(8): 14.     CrossRef
  • Management of portal hypertension severe complications
    Alberto ZANETTO, Giulio BARBIERO, Michele BATTISTEL, Salvatore S. SCIARRONE, Sarah SHALABY, Monica PELLONE, Sara BATTISTELLA, Martina GAMBATO, Giacomo GERMANI, Francesco P. RUSSO, Patrizia BURRA, Marco SENZOLO
    Minerva Gastroenterology.2021;[Epub]     CrossRef
  • Preloading Coil in Plug Method (p-CIP) with the AVP 2 for large Portosystemic Shunt Embolization
    Kazuki Hashimoto, Yukihisa Ogawa, Shinji Wada, Daichi Kobayashi, Shingo Hamaguchi, Junji Moriya, Hidefumi Mimura
    Radiology Case Reports.2021; 16(10): 2899.     CrossRef
  • Management of portal hypertensive upper gastrointestinal bleeding: Report of the Coorg Consensus workshop of the Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding
    Shivaram P. Singh, Manav Wadhawan, Subrat K. Acharya, Sawan Bopanna, Kaushal Madan, Manoj K. Sahoo, Naresh Bhat, Sri P. Misra, Ajay Duseja, Amar Mukund, Anil C. Anand, Ashish Goel, Bonthala S. Satyaprakash, Joy Varghese, Manas K. Panigrahi, Manu Tandan, M
    Indian Journal of Gastroenterology.2021; 40(5): 519.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • ACR Appropriateness Criteria® Radiologic Management of Gastric Varices
    Charles Y. Kim, Jason W. Pinchot, Osmanuddin Ahmed, Aaron R. Braun, Brooks D. Cash, Barry W. Feig, Sanjeeva P. Kalva, Erica M. Knavel Koepsel, Matthew J. Scheidt, Kristofer Schramm, David M. Sella, Clifford R. Weiss, Eric J. Hohenwalter
    Journal of the American College of Radiology.2020; 17(5): S239.     CrossRef
  • Managing liver cirrhotic complications: Overview of esophageal and gastric varices
    Cosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Gani
    Clinical and Molecular Hepatology.2020; 26(4): 444.     CrossRef
  • Change in Portal Pressure and Clinical Outcome in Cirrhotic Patients with Gastric Varices after Plug-Assisted Retrograde Transvenous Obliteration
    Jae Woo Park, Jeong-Ju Yoo, Sang Gyune Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Jae Myung Lee, Jong Joon Shim, Young Don Kim, Gab Jin Cheon, Baek Gyu Jun, Young Seok Kim
    Gut and Liver.2020; 14(6): 783.     CrossRef
  • Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis
    Keiji Yokoyama, Ryo Yamauchi, Kumiko Shibata, Hiromi Fukuda, Hideo Kunimoto, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka
    Clinical and Molecular Hepatology.2019; 25(2): 183.     CrossRef
  • Balloon-Assisted Percutaneous Transhepatic Antegrade Embolization with 2-Octyl Cyanoacrylate for the Treatment of Isolated Gastric Varices with Large Gastrorenal Shunts
    Guangchuan Wang, Dongxiao Meng, Guangjun Huang, Qingshan Pei, Lianhui Zhao, Yongjun Shi, Mingyan Zhang, Hua Feng, Junyong Zhang, Chunqing Zhang
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Management Options for Gastric Variceal Hemorrhage
    Edward Wolfgang Lee, Puja Shahrouki, Lourdes Alanis, Pengxu Ding, Stephen T. Kee
    JAMA Surgery.2019; 154(6): 540.     CrossRef
  • Update on management of gastric varices
    Louisa J Vine, Mohsan Subhani, Juan G Acevedo
    World Journal of Hepatology.2019; 11(3): 250.     CrossRef
  • Endoscopic Therapy and Radiologic Intervention of Acute Gastroesophageal Variceal Bleeding
    Jeong Eun Song, Byung Seok Kim
    Clinical Endoscopy.2019; 52(5): 407.     CrossRef
  • Treatment of Gastro-Fundal Varices (Including a Discussion of BRTO)
    Zachary Henry
    Current Hepatology Reports.2018; 17(3): 184.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Geunwu Gimm, Young Chang, Hyo-Cheol Kim, Aesun Shin, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2018; 12(6): 704.     CrossRef
  • Comparison of Transjugular Intrahepatic Portosystemic Shunt with Covered Stent and Balloon-Occluded Retrograde Transvenous Obliteration in Managing Isolated Gastric Varices
    Seung Kwon Kim, Kristen A. Lee, Steven Sauk, Kevin Korenblat
    Korean Journal of Radiology.2017; 18(2): 345.     CrossRef
  • Efficacy of Combined Balloon-occluded Retrograde Transvenous Obliteration and Simultaneous Endoscopic Injection Sclerotherapy
    Wataru Sato, Kentaro Kamada, Takashi Goto, Shigetoshi Ohshima, Kouichi Miura, Tomomi Shibuya, Takahiro Dohmen, Ryo Kanata, Toshitaka Sakai, Mitsuru Chiba, Yuko Sugimoto, Shinichiro Minami, Koichi Ishiyama, Manabu Hashimoto, Hirohide Ohnishi
    Internal Medicine.2015; 54(3): 261.     CrossRef
  • Vascular Plug–Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Varices and Hepatic Encephalopathy: A Prospective Multicenter Study
    Dong Il Gwon, Young Hwan Kim, Gi-Young Ko, Jong Woo Kim, Heung Kyu Ko, Jin Hyoung Kim, Ji Hoon Shin, Hyun-Ki Yoon, Kyu-Bo Sung
    Journal of Vascular and Interventional Radiology.2015; 26(11): 1589.     CrossRef
  • UK guidelines on the management of variceal haemorrhage in cirrhotic patients
    Dhiraj Tripathi, Adrian J Stanley, Peter C Hayes, David Patch, Charles Millson, Homoyon Mehrzad, Andrew Austin, James W Ferguson, Simon P Olliff, Mark Hudson, John M Christie
    Gut.2015; 64(11): 1680.     CrossRef
  • Endovascular Management of Gastric Varices
    Wael E. Saad
    Clinics in Liver Disease.2014; 18(4): 829.     CrossRef
  • Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results
    Edward W Lee, Sammy Saab, Antoinette S Gomes, Ronald Busuttil, Justin McWilliams, Francisco Durazo, Steven-Huy Han, Leonard Goldstein, Bashir A Tafti, John Moriarty, Christopher T Loh, Stephen T Kee
    Clinical and Translational Gastroenterology.2014; 5(10): e61.     CrossRef
  • Management of Gastric Varices
    Dushant Uppal, Zachary Henry, Abdullah Al-Osaimi, Wael Saad, Stephen Caldwell
    Current Hepatology Reports.2014; 13(3): 208.     CrossRef
  • Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder
    Robert Gianotti
    World Journal of Gastroenterology.2014; 20(39): 14495.     CrossRef
  • Update on gastric varices
    Maria Triantafyllou
    World Journal of Gastrointestinal Endoscopy.2014; 6(5): 168.     CrossRef
  • 12,883 View
  • 88 Download
  • Crossref

Steatotic liver disease

Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH
Min Yong Yoon, Jun Mo Sung, Chang Seok Song, Won Young Lee, Eun Jung Rhee, Jun Ho Shin, Chang Hak Yoo, Seoung Wan Chae, Ja Yeon Kim, Wook Jin, Yong Kyun Cho
Korean J Hepatol 2012;18(3):279-286.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.279
Background/Aims

Adipose tissue is an active endocrine organ that secretes various metabolically important substances including adipokines, which represent a link between insulin resistance and nonalcoholic steatohepatitis (NASH). The factors responsible for the progression from simple steatosis to steatohepatitis remain elusive, but adipokine imbalance may play a pivotal role. We evaluated the expressions of adipokines such as visfatin, adipocyte-fatty-acid-binding protein (A-FABP), and retinol-binding protein-4 (RBP-4) in serum and tissue. The aim was to discover whether these adipokines are potential predictors of NASH.

Methods

Polymerase chain reaction, quantification of mRNA, and Western blots encoding A-FABP, RBP-4, and visfatin were used to study tissue samples from the liver, and visceral and subcutaneous adipose tissue. The tissue samples were from biopsy specimens obtained from patients with proven NASH who were undergoing laparoscopic cholecystectomy due to gallbladder polyps.

Results

Patients were classified into two groups: NASH, n=10 and non-NASH, n=20 according to their nonalcoholic fatty liver disease Activity Score. Although serum A-FABP levels did not differ between the two groups, the expressions of A-FABP mRNA and protein in the visceral adipose tissue were significantly higher in NASH group than in non-NASH group (104.34 vs. 97.05, P<0.05, and 190.01 vs. 95.15, P<0.01, respectively). Furthermore, the A-FABP protein expression ratio between visceral adipose tissue and liver was higher in NASH group than in non-NASH group (4.38 vs. 1.64, P<0.05).

Conclusions

NASH patients had higher levels of A-FABP expression in their visceral fat compared to non-NASH patients. This differential A-FABP expression may predispose patients to the progressive form of NASH.

Citations

Citations to this article as recorded by  Crossref logo
  • The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
    Milton Packer
    JACC.2025; 86(16): 1269.     CrossRef
  • FABP4 Expression in Subcutaneous Adipose Tissue Is Independently Associated with Circulating Triglycerides in Obesity
    Óscar Osorio-Conles, Ainitze Ibarzabal, José María Balibrea, Josep Vidal, Emilio Ortega, Ana de Hollanda
    Journal of Clinical Medicine.2023; 12(3): 1013.     CrossRef
  • Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
    Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Lluís Masana, Ricardo Rodríguez-Calvo
    Biomedicines.2022; 10(1): 197.     CrossRef
  • Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
    Vera Francisco, Maria Jesus Sanz, José T. Real, Patrice Marques, Maurizio Capuozzo, Djedjiga Ait Eldjoudi, Oreste Gualillo
    Biology.2022; 11(8): 1237.     CrossRef
  • Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
    Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
    Journal of Clinical Medicine.2021; 10(14): 3029.     CrossRef
  • Serum adipocyte fatty acid‐binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus
    Min Ding, Jian‐Ying Shi, Yun‐Zhi XING, Bei Sun, Qian‐Hua Fang, Jing‐Yun Zhang, Qiu‐Mei Zhang, Li‐Ming Chen, De‐min Yu, Chun‐Jun Li
    Journal of Diabetes.2018; 10(6): 478.     CrossRef
  • Adipokines in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2016; 65(8): 1062.     CrossRef
  • Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review
    M. Bekaert, X. Verhelst, A. Geerts, B. Lapauw, P. Calders
    Obesity Reviews.2016; 17(1): 68.     CrossRef
  • Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography
    Chi-Sheng Hung, Yen-Wen Wu, Jei-Yie Huang, Pei-Ying Hsu, Ming-Fong Chen, Xin-Liang Ma
    PLoS ONE.2014; 9(5): e97710.     CrossRef
  • Serum visfatin in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, lordanis Romiopoulos, Vaia Polymerou
    Annals of Hepatology.2014; 13(1): 150.     CrossRef
  • Systems biology of adipose tissue metabolism: regulation of growth, signaling and inflammation
    Sara Manteiga, Kyungoh Choi, Arul Jayaraman, Kyongbum Lee
    WIREs Systems Biology and Medicine.2013; 5(4): 425.     CrossRef
  • Metabolically Protective Cytokines Adiponectin and Fibroblast Growth Factor-21 Are Increased by Acute Overfeeding in Healthy Humans
    Leonie K. Heilbronn, Lesley V. Campbell, Aimin Xu, Dorit Samocha-Bonet, Jose Galgani
    PLoS ONE.2013; 8(10): e78864.     CrossRef
  • 9,551 View
  • 78 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Tae Wan Kim, Hong Joo Kim, Chang Uk Chon, Hyun Sun Won, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Korean J Hepatol 2012;18(2):203-212.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.203
Background/Aims

Nonselective β-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis. A previous report suggested that survival was higher in patients receiving adjusted doses of NSBBs than in ligation patients. This study investigated whether low-dose NSBB medication has beneficial effects in patients with liver cirrhosis, especially in terms of overall survival.

Methods

We retrospectively studied 273 cirrhotic patients (199 males; age 53.6±10.2 years, mean±SD) who visited our institution between March 2003 and December 2007; follow-up data were collected until June 2011. Among them, 138 patients were given a low-dose NSBB (BB group: propranolol, 20-60 mg/day), and the remaining 135 patients were not given an NSBB (NBB group). Both groups were stratified randomly according to Child-Turcotte-Pugh (CTP) classification and age.

Results

The causes of liver cirrhosis were alcohol (n=109, 39.9%), hepatitis B virus (n=125, 45.8%), hepatitis C virus (n=20, 7.3%), and cryptogenic (n=19, 7.0%). The CTP classes were distributed as follows: A, n=116, 42.5%; B, n=126, 46.2%; and C, n=31, 11.4%. Neither the overall survival (P=0.133) nor the hepatocellular carcinoma (HCC)-free survival (P=0.910) differed significantly between the BB and NBB groups [probability of overall survival at 4 years: 75.1% (95% CI=67.7-82.5%) and 81.2% (95% CI=74.4-88.0%), respectively; P=0.236]. In addition, the delta CTP score did not differ significantly between the two groups.

Conclusions

Use of low-dose NSBB medication in patients with liver cirrhosis is not indicated in terms of overall and HCC-free survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
    Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
    He-Yun Cheng, Hsiu C. Lin, Hsiu L. Lin, Yow S. Uang, Joseph J. Keller, Li H. Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
    Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 1279.     CrossRef
  • Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy
    Pei-Chang Lee, Yu-Ju Chen, Yueh-Ching Chou, Kuei-Chuan Lee, Ping-Hsien Chen, Wei-Yu Kao, Yi-Hsiang Huang, Teh-Ia Huo, Han-Chieh Lin, Ming-Chih Hou, Fa-Yauh Lee, Jaw-Ching Wu, Chien-Wei Su
    European Journal of Gastroenterology & Hepatology.2020; 32(3): 365.     CrossRef
  • Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis
    Tzu-Hao Li, Yu-Lien Tsai, Chien-Fu Hsu, Chih-Wei Liu, Chia-Chang Huang, Ying-Ying Yang, Hung-Cheng Tsai, Shiang-Fen Huang, Yun-Cheng Hsieh, Hsuan-Miao Liu, Tzung-Yan Lee, Ming-Chih Hou, Chang-Youh Tsai, Han-Chieh Lin
    Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
  • Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center
    Nuretdin Suna, Diğdem Özer Etik, Serkan Öcal, Haldun Selçuk
    Experimental and Clinical Transplantation.2019; 17(5): 632.     CrossRef
  • Does Angiotensin‐Converting Enzyme Inhibitor and β‐Blocker Use Reduce the Risk of Primary Liver Cancer? A Case–Control Study Using the UK Clinical Practice Research Datalink
    Katrina Wilcox Hagberg, Vikrant V. Sahasrabuddhe, Katherine A. McGlynn, Susan S. Jick
    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2016; 36(2): 187.     CrossRef
  • The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
    Iván Herrera, Sonia Pascual, Pedro Zapater, Fernando Carnicer, Pablo Bellot, José María Palazón
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1194.     CrossRef
  • Non‐selective beta‐blockers may reduce risk of hepatocellular carcinoma: a meta‐analysis of randomized trials
    Maja Thiele, Agustín Albillos, Rozeta Abazi, Reiner Wiest, Lise L. Gluud, Aleksander Krag
    Liver International.2015; 35(8): 2009.     CrossRef
  • Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law
    Gerond Lake-Bakaar, Muneeb Ahmed, Amy Evenson, Alan Bonder, Salomao Faintuch, Vinay Sundaram
    Liver Cancer.2014; 3(3-4): 428.     CrossRef
  • Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
    Maja Thiele, Reiner Wiest, Lise Lotte Gluud, Agustín Albillos, Aleksander Krag
    Medical Hypotheses.2013; 81(5): 871.     CrossRef
  • 10,287 View
  • 56 Download
  • Crossref

Viral hepatitis

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection
Won Gil Chung, Hong Joo Kim, Young Gil Choe, Hyo Sun Seok, Chang Wook Chon, Yong Kyun Cho, Byung Ik Kim, Young Yool Koh
Korean J Hepatol 2012;18(2):195-202.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.195
Background/Aims

The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients.

Methods

The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identification Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment.

Results

A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not differ significantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was significantly lower among hazardous alcohol users (91.5% vs. 70.6%; P=0.033).

Conclusions

Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment. However, the ALT normalization rate at 12 months after initiation of ETV treatment was significantly lower among the hazardous alcohol users.

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of Alcohol Use on Nonalcohol-Related Liver Diseases
    Hanna Blaney, Ade Waterman, Alyson Kaplan
    Clinics in Liver Disease.2026; 30(1): 147.     CrossRef
  • Propensity Score Matching Analysis for Alcohol‐Related Liver Disease
    Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang
    Health Science Reports.2025;[Epub]     CrossRef
  • Liver and obesity: a narrative review
    Amedeo Lonardo, Ralf Weiskirchen
    Exploration of Medicine.2025;[Epub]     CrossRef
  • The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis
    Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy
    Frontiers in Gastroenterology.2024;[Epub]     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Yoosoo Chang, Seungho Ryu, Di Zhao, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak
    American Journal of Gastroenterology.2021; 116(2): 329.     CrossRef
  • Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment
    Ya‐Chao Tao, Meng‐Lan Wang, Dong‐Mei Zhang, Dong‐Bo Wu, Yong‐Hong Wang, Juan Liao, Hong Tang, En‐Qiang Chen
    Journal of Viral Hepatitis.2020; 27(7): 731.     CrossRef
  • Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
    Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu, Chun-Yen Lin
    BMC Gastroenterology.2020;[Epub]     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • Natural History and Treatment Indications of Chronic Hepatitis B
    Dong Hyun Sinn
    The Korean Journal of Gastroenterology.2019; 74(5): 245.     CrossRef
  • Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment
    Nam Hee Kim, Yong Kyun Cho, Byung Ik Kim, Hong Joo Kim
    Digestive Diseases and Sciences.2018; 63(10): 2792.     CrossRef
  • Hepatitis B virus infection and alcohol consumption
    Ayako Iida-Ueno, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada
    World Journal of Gastroenterology.2017; 23(15): 2651.     CrossRef
  • Emerging concepts in alcoholic hepatitis
    Phoenix Fung, Nikolaos Pyrsopoulos
    World Journal of Hepatology.2017; 9(12): 567.     CrossRef
  • Interaction of obesity and infections
    N. V. Dhurandhar, D. Bailey, D. Thomas
    Obesity Reviews.2015; 16(12): 1017.     CrossRef
  • Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B
    J. C. Hsiang, G. L.‐H. Wong, H. L.‐Y. Chan, A. W.‐H. Chan, A. M.‐L. Chim, V. W.‐S. Wong
    Alimentary Pharmacology & Therapeutics.2014; 40(6): 716.     CrossRef
  • 12,103 View
  • 78 Download
  • Crossref

Review

Revision and update on clinical practice guideline for liver cirrhosis
Ki Tae Suk, Soon Koo Baik, Jung Hwan Yoon, Jae Youn Cheong, Yong Han Paik, Chang Hyeong Lee, Young Seok Kim, Jin Woo Lee, Dong Joon Kim, Sung Won Cho, Seong Gyu Hwang, Joo Hyun Sohn, Moon Young Kim, Young Bae Kim, Jae Geun Kim, Yong Kyun Cho, Moon Seok Choi, Hyung Joon Kim, Hyun Woong Lee, Seung Up Kim, Ja Kyung Kim, Jin Young Choi, Dae Won Jun, Won Young Tak, Byung Seok Lee, Byoung Kuk Jang, Woo Jin Chung, Hong Soo Kim, Jae Young Jang, Soung Won Jeong, Sang Gyune Kim, Oh Sang Kwon, Young Kul Jung, Won Hyeok Choe, June Sung Lee, In Hee Kim, Jae Jun Shim, Gab Jin Cheon, Si Hyun Bae, Yeon Seok Seo, Dae Hee Choi, Se Jin Jang
Korean J Hepatol 2012;18(1):1-21.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.1

Citations

Citations to this article as recorded by  Crossref logo
  • GLOBE Score and UK‐PBC Risk Score Predict Long‐Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate
    Shu Xiang Li, Bu Er Li, Min Li, Sha Chen, Ting Ting Lyu, Qian Yi Wang, Xiao Ming Wang, Yu Wang, Hong Ma, Xiao Juan Ou, Yuan Yuan Kong, Xin Yan Zhao, Hong You, Wei Jia Duan, Ji Dong Jia
    Journal of Digestive Diseases.2025; 26(5-6): 250.     CrossRef
  • Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography
    Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • MetaLAB‐HOI: Template standardization of health outcomes enable massive and accurate detection of adverse drug reactions from electronic health records
    Suehyun Lee, Hyunah Shin, Seon Choe, Min‐Gyu Kang, Sae‐Hoon Kim, Dong Yoon Kang, Ju Han Kim
    Pharmacoepidemiology and Drug Safety.2024;[Epub]     CrossRef
  • Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena
    Mengqi Li, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Shan Shan, Min Li, Na Zeng, Qianyi Wang, Yuanyuan Kong, Hong Ma, Xinyan Zhao, Xiaojuan Ou, Hong You, Weijia Duan, Jidong Jia
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis
    Shouhao Wang, Zhewen Zhou, Chengan Xu, Hanzhu Chen, Wenya Ren, Xingdi Yang, Qiaoqiao Yin, Wei Zheng, Hongying Pan
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma
    Chang Hun Lee, Hye Jin Kang, Song Yi Yu, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • The Wnt/β-catenin signaling pathway plays a role in drug-induced liver injury by regulating cytochrome P450 2E1 expression
    Yoo-Sub Shin, Da-Bin Hwang, Dong-Hoon Won, Shin-Young Kim, Changuk Kim, Jun Won Park, Young Jeon, Jun-Won Yun
    Toxicological Research.2023; 39(3): 443.     CrossRef
  • Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
    Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim
    Medicina.2023; 59(8): 1436.     CrossRef
  • Concomitant gallstone disease was not associated with long‐term outcomes in ursodeoxycholic acid‐treated patients with primary biliary cholangitis
    Sha Chen, Meng Qi Li, Bu Er Li, Ting Ting Lv, Shu Xiang Li, Shan Shan, Min Li, Yuan Yuan Kong, Dong Zhang, Hong Ma, Xiao Juan Ou, Hong You, Wei Jia Duan, Ji Dong Jia
    Journal of Digestive Diseases.2023; 24(6-7): 419.     CrossRef
  • Reciprocal alterations in circulating and hepatic gamma–delta T cells in patients with primary biliary cholangitis
    Sha Chen, Tingting Lv, Guangyong Sun, Shuxiang Li, Weijia Duan, Chunpan Zhang, Hua Jin, Dan Tian, Mingyang Li, Shan Shan, Hong Ma, Xiaojuan Ou, Hong You, Dong Zhang, Jidong Jia
    Hepatology International.2022; 16(1): 195.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration
    Jung Hee Kim, Sung-Eun Kim, Do-Seon Song, Hee-Yeon Kim, Eileen Yoon, Tae-Hyung Kim, Young-Kul Jung, Ki Tae Suk, Baek-Gyu Jun, Hyung-Joon Yim, Jung-Hyun Kwon, Sung-Won Lee, Seong-Hee Kang, Moon-Young Kim, Soung-Won Jeong, Jae-Young Jang, Jeong-Ju Yoo, Sang
    Journal of Clinical Medicine.2022; 11(9): 2463.     CrossRef
  • Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis
    Sha Chen, Meng-Qi Li, Wei-Jia Duan, Bu-Er Li, Shu-Xiang Li, Ting-Ting Lv, Lin Ma, Ji-Dong Jia
    Hepatobiliary & Pancreatic Diseases International.2022; 21(6): 577.     CrossRef
  • Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
    Min-Jae Kim, Woo-Hyoung Kang, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park
    Journal of Clinical Medicine.2022; 11(19): 5897.     CrossRef
  • First experience of liver transplantation for HIV-positive patients in Russia
    M. S. Novruzbekov, V. A. Gulyaev, A. I. Mazus, E. V. Ivannikov, M. S. Yadrikhinskaya, K. N. Lutsyk, O. D. Olisov, R. B. Akhmetshin, K. M. Magomedov, B. I. Kazymov, A. R. Akhmedov, K. F. Alekberov, B. I. Yaremin
    Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2022; 12(6): 139.     CrossRef
  • Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B
    Hye Yeon Chon, Jae Seung Lee, Hye Won Lee, Ho Soo Chun, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Hepatology Research.2021; 51(4): 406.     CrossRef
  • Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites
    Jin Wook Lee, Jae Seok Hwang, Woo Jin Chung, Heon Ju Lee, Jung Gil Park, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Byoung Kuk Jang, Bhagwan Dass
    PLOS ONE.2021; 16(6): e0253886.     CrossRef
  • Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    The Korean Journal of Internal Medicine.2021; 36(Suppl 1): S1.     CrossRef
  • Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma
    Han Ah Lee, Young-Sun Lee, Beom Kyung Kim, Young Kul Jung, Seung Up Kim, Jun Yong Park, Ji Hoon Kim, Hyunggin An, Do Young Kim, Hyung Joon Yim, Sang Hoon Ahn, Jong Eun Yeon, Kwan Soo Byun, Kwang-Hyub Han, Soon Ho Um, Yeon Seok Seo
    Gut and Liver.2021; 15(3): 420.     CrossRef
  • Guidelines for Prevention and Treatment of Chronic Hepatitis B
    Guiqiang Wang, Zhongping Duan
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Ultrasonographic morphological diagnosis of chronic liver disease: 2-dimensional shear wave elastography as an add-on test
    Young Seo Cho, Woo Kyoung Jeong, Yongsoo Kim
    Ultrasonography.2020; 39(3): 272.     CrossRef
  • Toward Quantitative and Operator-independent Quasi-static Ultrasound Elastography: An Ex Vivo Feasibility Study
    Sathiyamoorthy Selladurai, Abhilash Verma, Arun K. Thittai
    Ultrasonic Imaging.2020; 42(4-5): 179.     CrossRef
  • A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus
    Min Cong, Xiaojuan Ou, Jian Huang, Jiang Long, Tong Li, Xueen Liu, Yanhong Wang, Xiaoning Wu, Jialing Zhou, Yameng Sun, Qinghua Shang, Guofeng Chen, Hui Ma, Wen Xie, Hongxin Piao, Yongping Yang, Zhiliang Gao, Xiaoyuan Xu, Zongnan Tan, Chitty Chen, Na Zeng
    OMICS: A Journal of Integrative Biology.2020; 24(7): 415.     CrossRef
  • Serum small extracellular vesicle‐derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma
    Soon Sun Kim, Geum Ok Baek, Hye Ri Ahn, Suna Sung, Chul Won Seo, Hyo Jung Cho, Suk Woo Nam, Jae Youn Cheong, Jung Woo Eun
    Molecular Oncology.2020; 14(10): 2646.     CrossRef
  • Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding
    Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Hyung Joon Yim, Young Kul Jung, Jin Mo Yang, Do Seon Song, Young Seok Kim, Sang Gyune Kim, Dong Joon Kim, Ki Tae Suk, Eileen L. Yoon, Sang Soo Lee, Chang Wook Kim, Hee Yeon Kim, Jae Young Jang, Soung Won Jeong
    Clinical and Molecular Hepatology.2020; 26(4): 540.     CrossRef
  • Managing liver cirrhotic complications: Overview of esophageal and gastric varices
    Cosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Gani
    Clinical and Molecular Hepatology.2020; 26(4): 444.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • The changing epidemiology of liver diseases in the Asia–Pacific region
    Martin C. S. Wong, Jason L. W. Huang, Jacob George, Junjie Huang, Colette Leung, Mohammed Eslam, Henry L. Y. Chan, Siew C. Ng
    Nature Reviews Gastroenterology & Hepatology.2019; 16(1): 57.     CrossRef
  • Fibrosis‐matched outcomes between chronic hepatitis B patients with drug‐induced virological response and inactive carriers
    Hye Soo Kim, Oidov Baatarkhuu, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang‐Hyub Han, Beom Kyung Kim, Seung Up Kim
    Liver International.2019; 39(1): 81.     CrossRef
  • Towards quantitative quasi-static ultrasound elastography using a reference layer for liver imaging application: A preliminary assessment
    Sathiyamoorthy Selladurai, Arun K. Thittai
    Ultrasonics.2019; 93: 7.     CrossRef
  • Prognosis of 732 ursodeoxycholic acid‐treated patients with primary biliary cholangitis: A single center follow‐up study from China
    Sha Chen, Weijia Duan, Min Li, Shuxiang Li, Tingting Lv, Qiuju Tian, Qianyi Wang, Xiaoning Wu, Xinyan Zhao, Xiaoming Wang, Yu Wang, Yuanyuan Kong, Hong Ma, Xiaojuan Ou, Hong You, Jidong Jia
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1236.     CrossRef
  • Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model
    Tatsuro Nishimura, Taro Takami, Ryo Sasaki, Yuki Aibe, Takashi Matsuda, Koichi Fujisawa, Toshihiko Matsumoto, Naoki Yamamoto, Kenji Tani, Yasuho Taura, Isao Sakaida, Matias A Avila
    PLOS ONE.2019; 14(1): e0210588.     CrossRef
  • Small Hepatocellular Carcinoma With Low Tumor Marker Expression Benefits More From Anatomical Resection Than Tumors With Aggressive Biology
    Dong-Hwan Jung, Shin Hwang, Young-Joo Lee, Ki-Hun Kim, Gi-Won Song, Chul-Soo Ahn, Deok-Bog Moon, Sung-Gyu Lee
    Annals of Surgery.2019; 269(3): 511.     CrossRef
  • Response-Related Factors of Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in Patients with Alcoholic Cirrhosis
    Haripriya Gupta, Gi Soo Youn, Sang Hak Han, Min Jea Shin, Sang Jun Yoon, Dae Hee Han, Na Young Lee, Dong Joon Kim, Soon Koo Baik, Ki Tae Suk
    Journal of Clinical Medicine.2019; 8(6): 862.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN)
    Ji Hoon Park, Mi-Suk Park, So Jung Lee, Woo Kyoung Jeong, Jae Young Lee, Min Jung Park, Sung Soo Lee, Kyunghwa Han, Chung Mo Nam, Seong Ho Park, Kyoung Ho Lee
    Radiology.2019; 292(3): 638.     CrossRef
  • Current approaches to the management of patients with cirrhotic ascites
    Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev
    World Journal of Gastroenterology.2019; 25(28): 3738.     CrossRef
  • The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients
    Tae Yeob Kim, Ki Tae Suk, Soung Won Jeong, Tom Ryu, Dong Joon Kim, Soon Koo Baik, Joo Hyun Sohn, Woo Kyoung Jeong, Eunhee Choi, Jae Young Jang, Moon Young Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • Natural History and Treatment Indications of Chronic Hepatitis B
    Dong Hyun Sinn
    The Korean Journal of Gastroenterology.2019; 74(5): 245.     CrossRef
  • Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B
    Mi Young Jeon, Hye Won Lee, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn
    Liver International.2018; 38(4): 676.     CrossRef
  • Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study
    Ki Tae Suk, Moon Young Kim, Soung Won Jeong, Jae Young Jang, Yoon Ok Jang, Soon Koo Baik
    Digestive Diseases and Sciences.2018; 63(1): 248.     CrossRef
  • Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes
    Tejasav Sehrawat, Anuraag Jindal, Paaras Kohli, Amit Thour, Jasbinder Kaur, Atul Sachdev, Yashdeep Gupta
    Diabetes Therapy.2018; 9(1): 243.     CrossRef
  • Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy
    Joohwan Bae, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Moon Seok Choi, Yong‐Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Liver International.2018; 38(8): 1442.     CrossRef
  • Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
    Weijia Duan, Xiaojuan Ou, Xiaoming Wang, Yu Wang, Xinyan Zhao, Qianyi Wang, Xiaoning Wu, Wei Zhang, Hong Ma, Hong You, Jidong Jia
    Revista Española de Enfermedades Digestivas.2018;[Epub]     CrossRef
  • Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D
    Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong
    Gut and Liver.2018; 12(4): 440.     CrossRef
  • Accumulation of citrullinated glial fibrillary acidic protein in a mouse model of bile duct ligation-induced hepatic fibrosis
    Sung-Eun Kim, Ji Won Park, Mo-Jong Kim, Byungki Jang, Yong-Chul Jeon, Hee-Jun Kim, Akihito Ishigami, Hyoung Su Kim, Ki Tae Suk, Dong Joon Kim, Choong Kee Park, Eun-Kyoung Choi, Myoung-Kuk Jang, Leo A. van Grunsven
    PLOS ONE.2018; 13(8): e0201744.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines for Ascites and Related Complications: What Has Been Changed from the 2011 KASL Clinical Practice Guidelines?
    Yeon Seok Seo
    The Korean Journal of Gastroenterology.2018; 72(4): 179.     CrossRef
  • Iron metabolism disorders in patients with hepatitis B-related liver diseases
    Yan-Hang Gao, Jing-Yun Wang, Pei-Yan Liu, Jing Sun, Xiao-Mei Wang, Rui-Hong Wu, Xiu-Ting He, Zheng-Kun Tu, Chun-Guang Wang, Hong-Qin Xu, Jun-Qi Niu
    World Journal of Clinical Cases.2018; 6(13): 600.     CrossRef
  • Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection
    Yangxin Xie, Bo Tu, Xin Zhang, Jingfeng Bi, Lei Shi, Peng Zhao, Weiwei Chen, Suxia Liu, Dongping Xu, Enqiang Qin
    Oncotarget.2018; 9(3): 3980.     CrossRef
  • Alcoholic Liver Disease Is Associated with an Increased Risk of Gastric Cancer
    Tae Hoon Ha, Byeong Gwan Kim, Donghyong Jeong, Sohee Oh, Won Kim, Yong Jin Jung, Dong Won Ahn, Ji Bong Jeong, Ji Won Kim, Kook Lae Lee, Seong-Joon Koh
    Digestive Diseases and Sciences.2017; 62(1): 273.     CrossRef
  • Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites
    Sun Hee Na, Eun Jung Kim, Eun Young Nam, Kyoung-Ho Song, Pyoeng Gyun Choe, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Sang Won Park, Hong Bin Kim, Myoung-don Oh, Nam Joong Kim
    Scandinavian Journal of Gastroenterology.2017; 52(2): 199.     CrossRef
  • Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis
    Eui Joo Kim, Jong Eun Yeon, Oh Sang Kwon, Heon Nam Lee, Seung Kak Shin, Seong Hee Kang, Kwan Soo Byun, Jeong Han Kim, So Young Kwon, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim
    Digestive Diseases and Sciences.2017; 62(3): 808.     CrossRef
  • Clinical Features of Spontaneous Bacterial Peritonitis: A 10-year Experience from a Single Center
    Ha Young Na, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    The Korean Journal of Gastroenterology.2017; 69(2): 129.     CrossRef
  • Do We Need to Change the Treatment Strategy for Spontaneous Bacterial Peritonitis in Patients with Advanced Cirrhosis?
    Chang Wook Kim
    The Korean Journal of Gastroenterology.2017; 69(2): 93.     CrossRef
  • Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial
    Ji Hoon Park, Mi-Suk Park, So Jung Lee, Woo Kyoung Jeong, Jae Young Lee, Min Jung Park, Kyunghwa Han, Chung Mo Nam, Seong Ho Park, Kyoung Ho Lee
    BMC Cancer.2017;[Epub]     CrossRef
  • Prognostic effect of transarterial chemoembolization–induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma
    Woo‐Hyoung Kang, Shin Hwang, Gi‐Won Song, Young‐Joo Lee, Ki‐Hun Kim, Chul‐Soo Ahn, Deok‐Bog Moon, Dong‐Hwan Jung, Gil‐Chun Park, Sung‐Gyu Lee
    Liver Transplantation.2017; 23(6): 781.     CrossRef
  • Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
    Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong
    Gut and Liver.2017; 11(4): 543.     CrossRef
  • Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues
    Dong Joon Kim, Moon Seok Choi
    Clinical and Molecular Hepatology.2017; 23(2): 115.     CrossRef
  • 3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy
    Chang Hun Lee, In Hee Kim, Jin Chang Moon, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Jae Do Yang, Hee Chul Yu
    World Journal of Gastroenterology.2017; 23(2): 297.     CrossRef
  • Liver cirrhosis caused by chronic Budd–Chiari syndrome
    Mengjie Lin, Feng Zhang, Yi Wang, Bin Zhang, Wei Zhang, Xiaoping Zou, Ming Zhang, Yuzheng Zhuge
    Medicine.2017; 96(34): e7425.     CrossRef
  • Hospice and Palliative Care in End Stage Liver Disease
    Moon Young Kim
    The Korean Journal of Hospice and Palliative Care.2017; 20(3): 167.     CrossRef
  • Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B
    Wei Zhang, Xiaoming Wang, Yu Wang, Xinyan Zhao, Weijia Duan, Qianyi Wang, Xiaoning Wu, Yuanyuan Kong, Hong Ma, Hong You, Xiaojuan Ou, Jidong Jia
    Medicine.2017; 96(44): e8454.     CrossRef
  • Useful Endoscopic Ultrasonography Parameters and a Predictive Model for the Recurrence of Esophageal Varices and Bleeding after Variceal Ligation
    Soung Won Jeong, Hye Soo Kim, Sang Gyune Kim, Jeong-Ju Yoo, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Ji Sung Lee, Young Seok Kim, Boo Sung Kim
    Gut and Liver.2017; 11(6): 843.     CrossRef
  • FATORES PROGNÓSTICOS E MORTALIDADE EM PACIENTES CIRRÓTICOS QUE FORAM INTERNADOS COM HEMORRAGIA DIGESTIVA ALTA VARICOSA EM UM HOSPITAL PÚBLICO
    Haroldo Luiz Jordelino da Luz, Caroline de Medeiros Linhares, Luana Fanha Souto, Bruna Luiza Zonta Ximenes Canfield, Ariane Badotti
    Arquivos Catarinenses de Medicina.2017; 46(1): 97.     CrossRef
  • Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis
    Tae Yeob Kim, Jae Gon Lee, Joo Hyun Sohn, Ji Yeoun Kim, Sun Min Kim, Jinoo Kim, Woo Kyoung Jeong
    Yonsei Medical Journal.2016; 57(1): 138.     CrossRef
  • The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?
    Sun Young Yim, Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim, Jae Min Lee, Eun Sun Kim, Bora Keum, Young Kul Jong, Hyunggin An, Ji Hoon Kim, Hyung Joon Yim, Dong Sik Kim, Yoon Tae Jeen, Jong Eun Yeon, Hong Sik Lee, Hoon Jai Chun, Kwan Soo Byun, Soon Ho Um,
    Liver International.2016; 36(3): 445.     CrossRef
  • Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma
    Tae‐Yong Ha, Shin Hwang, Young‐Joo Lee, Ki‐Hun Kim, Gi‐Young Ko, Dong II Gwon, Chul‐Soo Ahn, Deok‐Bog Moon, Gi‐Won Song, Dong‐Hwan Jung, Han Chu Lee, Young‐Suk Lim, Kang Mo Kim, Ju Hyun Shim, Jeong‐Heon Choi, Sung‐Gyu Lee
    World Journal of Surgery.2016; 40(5): 1200.     CrossRef
  • Proton Pump Inhibitor Therapy Is Associated With Reduction of Early Bleeding Risk After Prophylactic Endoscopic Variceal Band Ligation
    Seong Hee Kang, Hyung Joon Yim, Seung Young Kim, Sang Jun Suh, Jong Jin Hyun, Sung Woo Jung, Young Kul Jung, Ja Seol Koo, Sang Woo Lee
    Medicine.2016; 95(8): e2903.     CrossRef
  • Variceal Bleeding from Anastomosis Site after Total Gastrectomy with Esophagojejunostomy
    Jung Woong Seo, Jeong Han Kim
    The Korean Journal of Gastroenterology.2016; 67(6): 341.     CrossRef
  • Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma
    Jung Hee Kim, Dong Hyun Sinn, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Digestive Diseases and Sciences.2016; 61(11): 3354.     CrossRef
  • Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B
    Hye Soo Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Ki Jun Song, Jung Won Park, Yeong Jin Kim, Oidov Baatarkhuu, Kwang-Hyub Han, Sang Hoon Ahn
    Clinical Gastroenterology and Hepatology.2016; 14(11): 1647.     CrossRef
  • Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease
    Bong Jin Ko, Young Seok Kim, Sang Gyune Kim, Jung Hwan Park, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim, Sun Mi Kim, Young Don Kim, Gab Jin Cheon, Bo Ra Lee
    Gut and Liver.2016; 10(5): 818.     CrossRef
  • Transplantation with autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial
    Ki Tae Suk, Jung‐Hwan Yoon, Moon Young Kim, Chang Wook Kim, Ja Kyung Kim, Hana Park, Seong Gyu Hwang, Dong Joon Kim, Byung Seok Lee, Sae Hwan Lee, Hong Soo Kim, Jae Young Jang, Chang‐Hyeong Lee, Byung Seok Kim, Yoon Ok Jang, Mee Yon Cho, Eun Sun Jung, Yon
    Hepatology.2016; 64(6): 2185.     CrossRef
  • Usefulness of Ultrasonographic Scoring System in Diagnosis of Alcoholic Cirrhosis
    Kyoung Min Moon, Soon Koo Baik
    Clinical Ultrasound.2016; 1(2): 92.     CrossRef
  • Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition
    Tae Yeob Kim, Do Seon Song, Hee Yeon Kim, Dong Hyun Sinn, Eileen L. Yoon, Chang Wook Kim, Young Kul Jung, Ki Tae Suk, Sang Soo Lee, Chang Hyeong Lee, Tae Hun Kim, Jeong Han Kim, Won Hyeok Choe, Hyung Joon Yim, Sung Eun Kim, Soon Koo Baik, Byung Seok Lee,
    PLOS ONE.2016; 11(1): e0146745.     CrossRef
  • Clinical features of acute hepatitis E super-infections on chronic hepatitis B
    Chong Chen, Shu-Ye Zhang, Dan-Dan Zhang, Xin-Yan Li, Yu-Ling Zhang, Wei-Xia Li, Jing-Jing Yan, Min Wang, Jing-Na Xun, Chuan Lu, Yun Ling, Yu-Xian Huang, Liang Chen
    World Journal of Gastroenterology.2016; 22(47): 10388.     CrossRef
  • Long-Term Suppression of Viral Replication in Chronic Hepatitis B: Outcomes and Future Directions
    Jae-Jun Shim
    Gut and Liver.2015;[Epub]     CrossRef
  • Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma
    Jeong-Heon Choi, Shin Hwang, Young-Joo Lee, Ki-Hun Kim, Gi-Young Ko, Dong Il Gwon, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Sung-Gyu Lee
    Korean Journal of Hepato-Biliary-Pancreatic Surgery.2015; 19(2): 59.     CrossRef
  • The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
    In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
    Clinical and Molecular Hepatology.2015; 21(1): 32.     CrossRef
  • The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients
    Shin Hwang, Young-Joo Lee, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Sung-Gyu Lee
    Journal of Gastrointestinal Surgery.2015; 19(7): 1281.     CrossRef
  • Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy
    Jin Chang Moon, Seong Hun Kim, In Hee Kim, Chang Hun Lee, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae-Ghon Kim
    Gut and Liver.2015;[Epub]     CrossRef
  • Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
    Chansoo Moon, Kyu Sik Jung, Do Young Kim, Oidov Baatarkhuu, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Sang Hoon Ahn, Kwang-Hyub Han
    Digestive Diseases and Sciences.2015; 60(2): 573.     CrossRef
  • Improvement of liver function and non‐invasive fibrosis markers in hepatitis B virus‐associated cirrhosis: 2 years of entecavir treatment
    Seung Kak Shin, Jeong Han Kim, Hyeonsu Park, Oh Sang Kwon, Hyun Jung Lee, Jong Eun Yeon, Kwan Soo Byun, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim
    Journal of Gastroenterology and Hepatology.2015; 30(12): 1775.     CrossRef
  • Evaluation of portal hypertension by real‐time shear wave elastography in cirrhotic patients
    Tae Yeob Kim, Woo Kyoung Jeong, Joo Hyun Sohn, Jinoo Kim, Min Yeong Kim, Yongsoo Kim
    Liver International.2015; 35(11): 2416.     CrossRef
  • Liver Stiffness Measurement, Better than APRI, Fibroindex, Fib-4, and NBI Gastroscopy, Predicts Portal Hypertension in Patients with Cirrhosis
    Wei Zhang, Liqiong Wang, Lei Wang, Gang Li, Aoshuang Huang, Ping Yin, Zhenhua Yang, Changquan Ling, Lingtai Wang
    Cell Biochemistry and Biophysics.2015; 71(2): 865.     CrossRef
  • What we know about paracentesis induced circulatory dysfunction?
    Jeong Han Kim
    Clinical and Molecular Hepatology.2015; 21(4): 349.     CrossRef
  • Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B
    Hyo Jung Cho, Soon Sun Kim, Seun Joo Ahn, Joo Han Park, Dong Joon Kim, Young Bae Kim, Sung Won Cho, Jae Youn Cheong
    Clinical and Molecular Hepatology.2014; 20(4): 347.     CrossRef
  • Prevention of Variceal Rebleeding According to the Dose of Propranolol
    Jae Young Jang, Woong Cheul Lee
    Korean Journal of Medicine.2014; 86(1): 30.     CrossRef
  • Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites
    Tae Yeob Kim, Min Yeong Kim, Joo Hyun Sohn, Sun Min Kim, Jeong Ah Ryu, Sanghyeok Lim, Youngsoo Kim
    Journal of Korean Medical Science.2014; 29(9): 1253.     CrossRef
  • Clinically Severe Portal Hypertension: Role of Multi-detector Row CT Features in Diagnosis
    Ji Young Lee, Tae Yeob Kim, Woo Kyoung Jeong, Yongsoo Kim, Jinoo Kim, Kyoung Won Kim, Young Hwan Kim, Joo Hyun Sohn
    Digestive Diseases and Sciences.2014; 59(9): 2333.     CrossRef
  • Cyanoacrylate Injection Compared with Band Ligation for Acute Gastric Variceal Hemorrhage: A Meta-Analysis of Randomized Controlled Trials and Observational Studies
    Xiaohua Ye, Jiaping Huai, Yanping Chen
    Gastroenterology Research and Practice.2014; 2014: 1.     CrossRef
  • Clinical Features of Non-alcoholic Fatty Liver Disease in Cryptogenic Hepatocellular Carcinoma
    Min Young Rim, Oh Sang Kwon, Minsu Ha, Ju Seung Kim, Kwang Il Ko, Dong Kyu Kim, Pil Kyu Jang, Jung Yoon Han, Pyung Hwa Park, Young Kul Jung, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
    The Korean Journal of Gastroenterology.2014; 63(5): 292.     CrossRef
  • Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study
    Yoon Ok Jang, Young Ju Kim, Soon Koo Baik, Moon Young Kim, Young Woo Eom, Mee Yon Cho, Hong Jun Park, So Yeon Park, Bo Ra Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Eun Hee Choi, Yong Man Kim
    Liver International.2014; 34(1): 33.     CrossRef
  • Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease
    Won Ki Hong, Kwang Yong Shim, Soon Koo Baik, Moon Young Kim, Mee Yon Cho, Yoon Ok Jang, Young Shik Park, Jin Han, Gaeun Kim, Youn Zoo Cho, Hye Won Hwang, Jin Hyung Lee, Myeong Hun Chae, Sang Ok Kwon
    Journal of Korean Medical Science.2014; 29(3): 392.     CrossRef
  • Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker
    Tae Seop Lim, Beom Kyung Kim, Jong Wook Lee, Young Ki Lee, Sooyun Chang, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park, Charles C. Caldwell
    PLoS ONE.2014; 9(1): e86884.     CrossRef
  • Alcoholic liver disease: Treatment
    Ki Tae Suk
    World Journal of Gastroenterology.2014; 20(36): 12934.     CrossRef
  • Association of polymorphism in MicroRNA 219‐1 with clearance of hepatitis B virus infection
    Jae Youn Cheong, Hyoung Doo Shin, Yoon Jun Kim, Sung Won Cho
    Journal of Medical Virology.2013; 85(5): 808.     CrossRef
  • Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection
    Chang Bum Bae, Soon Sun Kim, Seun Joo Ahn, Hyo Jung Cho, Sei Rhan Kim, Sun Young Park, Ga Won Song, Dong Joon Kim, Seong Gyu Hwang, Jin Mo Yang, Young Bae Kim, Young Nyun Park, Sung Jae Shin, Sung Won Cho, Jae Youn Cheong
    Journal of Clinical Virology.2013; 58(4): 641.     CrossRef
  • The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data
    Won Ki Hong, Moon Young Kim, Soon Koo Baik, Seung Yong Shin, Jung Min Kim, Yong Seok Kang, Yoo Li Lim, Young Ju Kim, Youn Zoo Cho, Hye Won Hwang, Jin Hyung Lee, Myeong Hun Chae, Hyoun A Kim, Hye Won Kang, Sang Ok Kwon
    Clinical and Molecular Hepatology.2013; 19(4): 370.     CrossRef
  • Prevention and Management of Variceal Hemorrhage
    Dong Hyun Kim, Jun Yong Park
    International Journal of Hepatology.2013; 2013: 1.     CrossRef
  • Comparison of Endoscopic Variceal Ligation and Endoscopic Variceal Obliteration in Patients with GOV1 Bleeding
    Hyoung Ju Hong, Chung Hwan Jun, Du Hyeon Lee, Eun Ae Cho, Seon Young Park, Sung Bum Cho, Chang Hwan Park, Young Eun Joo, HyunSoo Kim, Sung Kyu Choi, Jong Sun Rew
    Chonnam Medical Journal.2013; 49(1): 14.     CrossRef
  • The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011
    Jae-Jun Shim, Hyun Jin Park, Jung-Wook Kim, Eun Jung Hwang, Chang Kyun Lee, Jae Young Jang, Seong Jin Park, Hyun Rim Choi, Byung-Ho Kim
    Korean Journal of Medicine.2013; 84(5): 672.     CrossRef
  • Spontaneous Healing of Gastric Perforation after Endoscopic Ligation for Gastric Varices
    Jung Ho Kim, Hong Dae Ahn, Kwang An Kwon, Yoon Jae Kim, Jun-Won Chung, Dong Kyun Park, Ju Hyun Kim
    Journal of Korean Medical Science.2013; 28(4): 624.     CrossRef
  • A Case of Spontaneous Bacterial Peritonitis Caused byListeria monocytogenes
    Byung Sihk Kim, Tae Yeob Kim, Ji Yeoun Kim, Kyo Sang Yoo, Yong Chul Jeon, Dong Soo Han, Joo Hyun Sohn, Jieun Kim
    The Korean Journal of Gastroenterology.2013; 62(3): 179.     CrossRef
  • Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study
    Se Young Jang, Go Heun Kim, Soo Young Park, Chang Min Cho, Won Young Tak, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Jae Myeong Lee, Sang Gyune Kim, Dae Yong Kim, Young Seok Kim, Se-Ok Lee, Yang Won Min, Joon Hyeok Lee, Seung Woon Paik, Byung Chul Yoo,
    Clinical and Molecular Hepatology.2012; 18(4): 368.     CrossRef
  • Spontaneous Bacterial Peritonitis with Sepsis Caused byEnterococcus hirae
    Jong Seop Sim, Hyoung Su Kim, Ki Jong Oh, Myung Soo Park, Eun Ju Jung, Youn Joo Jung, Dae Gil Kang, Seung In Seo, Won Jin Kim, Myoung Kuk Jang
    Journal of Korean Medical Science.2012; 27(12): 1598.     CrossRef
  • 65,535 View
  • 190 Download
  • Crossref
Original Articles
Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis
Woo Jin Lee, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Korean J Hepatol 2011;17(4):292-298.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.292
Background/Aims

Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem. Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with refractory hepatic hydrothorax.

Methods

Eleven consecutive patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical records and radiologic imagings of these patients were thoroughly reviewed.

Results

The median number of chemical pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%), 5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks). Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%), azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall survival was significantly longer in the success group than in the non-success group.

Conclusions

Although chemical pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine application of this procedure for such patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis
    Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita
    Cureus.2025;[Epub]     CrossRef
  • Hepatic hydrothorax as a manifestation of decompensated cirrhosis: An update on current management and future directions
    Brandon-Joe Cilia, James Haridy, Ashok Raj, Nicholas Hannah
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Positionspapier für die standardisierte Anwendung von Transjugulärem Intrahepatischem Portosystemischem Shunt (TIPS) bei Erwachsenen
    Jonel Trebicka, Christian Steib, Alexander Zipprich, Cristina Ripoll, Johannes Kluwe, Michael Schultheiß, Andreas A. Schnitzbauer, Bernhard Meyer, Christian Jansen, Hauke Heinzow, Philipp Papprottka, Carsten Meyer, Max Seidensticker, Harald Ittrich, Frank
    Zeitschrift für Gastroenterologie.2025; 63(11): 1149.     CrossRef
  • Effectiveness of Chemical Pleurodesis Using Doxycycline in Malignant and Nonmalignant Pleural Disorders: A Retrospective Study from Rural South India
    Bimal Raj Rajalingam, Priya R Panicker, Archana L Peethambaran, Alexander Jenish Babu, Ravichandran Vijayakumar
    Indian Journal of Respiratory Care.2024; 12(4): 299.     CrossRef
  • Pleural Port-A-Cath for Symptomatic Refractory Hepatic Hydrothorax in Nontransplant Liver Patients
    Khaled Alshabani, Estefania Rivera, Alichia Paton, Juan Camilo Lara, Sebastian Fernandez-Bussy, Adnan Majid
    Annals of the American Thoracic Society.2024; 21(5): 823.     CrossRef
  • Medical thoracoscopy with talc pleurodesis for refractory hepatic hydrothorax: A case series of three successes
    Y. Rahim, R.V. Reddy, M. Naeem, G. Tsaknis
    Respiratory Medicine Case Reports.2024; 50: 102039.     CrossRef
  • ERS statement on benign pleural effusions in adults
    Anand Sundaralingam, Elzbieta M. Grabczak, Patrizia Burra, M. Inês Costa, Vineeth George, Eli Harriss, Ewa A. Jankowska, Julius P. Janssen, Georgia Karpathiou, Christian B. Laursen, Kornelija Maceviciute, Nick Maskell, Federico Mei, Blin Nagavci, Vasiliki
    European Respiratory Journal.2024; 64(6): 2302307.     CrossRef
  • Pulmonary complications of portal hypertension: The overlooked decompensation
    Rares Craciun, Tudor Mocan, Bogdan Procopet, Andrada Nemes, Cristian Tefas, Mihaela Sparchez, Lavinia-Patricia Mocan, Zeno Sparchez
    World Journal of Clinical Cases.2022; 10(17): 5531.     CrossRef
  • Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
    Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
    The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248.     CrossRef
  • Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
    Daniela Matei, Rares Craciun, Dana Crisan, Bogdan Procopet, Tudor Mocan, Sergiu Pasca, Roxana Zaharie, Bogdan Popovici, Zeno Sparchez
    Journal of Clinical Medicine.2021; 10(16): 3688.     CrossRef
  • Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance
    Bubu A. Banini, Yahya Alwatari, Madeline Stovall, Nathan Ogden, Evgeni Gershman, Rachit D. Shah, Brian J. Strife, Samira Shojaee, Richard K. Sterling
    Hepatology.2020; 72(5): 1851.     CrossRef
  • Hepatic Hydrothorax: An Updated Review on a Challenging Disease
    Toufic Chaaban, Nadim Kanj, Imad Bou Akl
    Lung.2019; 197(4): 399.     CrossRef
  • Hepatic Hydrothorax
    Yong Lv, Guohong Han, Daiming Fan
    Annals of Hepatology.2018; 17(1): 33.     CrossRef
  • Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
    Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
    Egyptian Journal of Bronchology.2018; 12(1): 98.     CrossRef
  • Diagnóstico y manejo de los trasudados pleurales
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología.2017; 53(11): 629.     CrossRef
  • Diagnosis and Management of Pleural Transudates
    Lucía Ferreiro, José M. Porcel, Luis Valdés
    Archivos de Bronconeumología (English Edition).2017; 53(11): 629.     CrossRef
  • Chemical pleurodesis by small bore catheter in hepatic hydrothorax: A feasibility study
    Asem A. Hewidy, Nasef Abdelsalam A. Rezk, Ahmed Abdel-Razik
    Egyptian Journal of Chest Diseases and Tuberculosis.2016; 65(1): 187.     CrossRef
  • Pigtail Catheter: A Less Invasive Option for Pleural Drainage in Egyptian Patients with Recurrent Hepatic Hydrothorax
    Mohamed Sharaf-Eldin, Adel Salah Bediwy, Abdelrahman Kobtan, Sherief Abd-Elsalam, Ferial El-Kalla, Loai Mansour, Walaa Elkhalawany, Mohamed Elhendawy, Samah Soliman
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis
    Feifei Hou, Xingshun Qi, Xiaozhong Guo
    Digestive Diseases and Sciences.2016; 61(11): 3321.     CrossRef
  • Hepatic hydrothorax: clinical review and update on consensus guidelines
    Rana Khazar Al-Zoubi, Mouhanna Abu Ghanimeh, Ashraf Gohar, Gary A. Salzman, Osama Yousef
    Hospital Practice.2016; 44(4): 213.     CrossRef
  • The management of benign non-infective pleural effusions
    Oliver J. Bintcliffe, Gary Y.C. Lee, Najib M. Rahman, Nick A. Maskell
    European Respiratory Review.2016; 25(141): 303.     CrossRef
  • Ultrasound-guided pleurodesis with doxycycline in patients with hepatic hydrothorax
    Ahmed M. Abd El Hafeez, Waleed F. Fathallah
    Egyptian Journal of Bronchology.2016; 10(1): 20.     CrossRef
  • Efficacy of nonsurgical tigecycline pleurodesis for the management of hepatic hydrothorax in patients with liver cirrhosis
    Nevin Yilmaz, Arife Zeybek, Benjamin Tharian, Ugur Eser Yilmaz
    Surgical Case Reports.2015;[Epub]     CrossRef
  • Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine
    Junichi Senoo, Tetsuhiro Chiba, Tomoko Saito, Yoshihiko Ooka, Sadahisa Ogasawara, Hirotaka Koseki, Naoya Kanogawa, Eiichiro Suzuki, Akinobu Tawada, Osamu Yokosuka
    Kanzo.2015; 56(5): 213.     CrossRef
  • Management of refractory hepatic hydrothorax
    José M. Porcel
    Current Opinion in Pulmonary Medicine.2014; 20(4): 352.     CrossRef
  • Hepatic Hydrothorax
    John Paul Norvell, James R. Spivey
    Clinics in Liver Disease.2014; 18(2): 439.     CrossRef
  • Indwelling pleural catheters for benign pleural effusions
    O. J. Bintcliffe, D. T. Arnold, N. A. Maskell
    Current Respiratory Care Reports.2014; 3(2): 61.     CrossRef
  • Symptomatic hepatic hydrothorax successfully treated with transjugular intrahepatic portosystemic shunt (TIPS)–role of titration of portosystemic gradient reduction to avoid post‐TIPS encephalopathy
    T. L. Krishnamoorthy, M. Taneja, P. E. Chang
    Clinical Case Reports.2014; 2(3): 93.     CrossRef
  • Hidrotórax de causa hepática: análisis de 77 pacientes
    José M. Porcel, Estela Mas, Josep M. Reñé, Silvia Bielsa
    Medicina Clínica.2013; 141(11): 484.     CrossRef
  • Paradigms in the management of hepatic hydrothorax: past, present, and future
    Sachin Kumar, Shiv Kumar Sarin
    Hepatology International.2013; 7(1): 80.     CrossRef
  • Evidence-Based Review of the Management of Hepatic Hydrothorax
    Amita Singh, Abubakr Bajwa, Adil Shujaat
    Respiration.2013; 86(2): 155.     CrossRef
  • 11,415 View
  • 64 Download
  • Crossref
A study of the awareness of chronic liver diseases among Korean adults
Dae Won Jun, Yong Kyun Cho, Joo Hyun Sohn, Chang Hyeong Lee, Seok Hyun Kim, Jong Ryul Eun
Korean J Hepatol 2011;17(2):99-105.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.99
Background/Aims

Chronic liver disease is closely associated with lifestyle, and public enlightenment of the lifestyle factors is important in reducing prevalence of chronic liver disease. The KASL (Korean Association for the Study of the Liver) conducted a survey of basic information and epidemiological data regarding chronic liver diseases.

Methods

A survey of chronic liver disease involving a total of 2,794 respondents was conducted. The respondents included patients and their guardians, visitors for health check-ups, and online pollees who completed a questionnaire on the awareness of fatty liver or chronic liver disease.

Results

Of the entire cohort, 854 (39.7%) said they have had or still have fatty liver or an elevated transaminase level (>40 IU/L), but only 23.4% of the respondents had visited a hospital. It was found that 35% of healthy subjects and 45% of patients and their guardians misunderstood hepatitis B as the hereditary disesase. Furthermore, 26% of the subjects responded that patients with inactive hepatitis B do not require regular follow-up. While 17.9% answered that it is not too late to test for liver cancer when symptoms arise, 38.8% believed that liver transplant in liver cancer patients has a low success rate and is thus not recommended.

Conclusions

Despite the inundation of information and widespread media advertising, the awareness of chronic liver disease is unsatisfactory among Korean adults. Systematic nationwide studies are needed to obtain data and information regarding the prevalence of chronic liver disease and patterns of use of the health-care system.

Citations

Citations to this article as recorded by  Crossref logo
  • Understanding Hepatitis B Knowledge, Attitudes, and Stigma in the Korean Community in Australia
    Youngnam Baek, Robyn Horwitz, Loren Brener, Sylvester Okeke, Tim Broady, Carla Treloar, Elena Cama
    Journal of Racial and Ethnic Health Disparities.2025;[Epub]     CrossRef
  • Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
    Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
    Heliyon.2024; 10(22): e40217.     CrossRef
  • Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
    Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, Pietro Lampertico, Maria Buti, Claude B. Sirlin, Mindie H. Nguyen, Rohit Loomba
    Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 797.     CrossRef
  • Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study
    Mei Hsuan Lee, Sang Hoon Ahn, Henry L. Y. Chan, Asad Choudhry, Rino Alvani Gani, Rosmawati Mohamed, Janus P. Ong, Akash Shukla, Chee Kiat Tan, Tawesak Tanwandee, Pham Thi Thu Thuy, Boon Leong Neo, Venus Tsang, Jin Youn, Shikha Singh
    Journal of Viral Hepatitis.2022; 29(2): 156.     CrossRef
  • The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
    Naim Alkhouri, Ashraf Almomani, Phuc Le, Julia Y. Payne, Imad Asaad, Celine Sakkal, Miriam Vos, Mazen Noureddin, Prabhat Kumar
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study
    Ammal M. Metwally, Dalia M. Elmosalami, Hazem Elhariri, Lobna A. El Etreby, Ahmed Aboulghate, Marwa M. El-Sonbaty, Amira Mohsen, Rehan M. Saleh, Ghada A. Abdel-Latif, Sahar Samy, Sherif E. El Deeb, Asmaa M. Fathy, Mohab M. Salah, Mohamed A. Abdel Mawla, H
    PLOS ONE.2021; 16(2): e0242257.     CrossRef
  • Self-testing for liver disease – response to an online liver test questionnaire
    Achim Kautz, Rebecca Dorner, Christoph Antoni, Matthias Ebert, Andreas Teufel
    Scandinavian Journal of Gastroenterology.2020; 55(1): 67.     CrossRef
  • Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals
    Saikat Banerjee, Sampada Kumar Dash
    Health Marketing Quarterly.2018; 35(2): 134.     CrossRef
  • Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
    Ho Hyun Nam, Dae Won Jun, Kiseok Jang, Waqar Khalid Saeed, Jai Sun Lee, Hyeon Tae Kang, Yeon Ji Chae
    Oncotarget.2017; 8(58): 97965.     CrossRef
  • Usefulness of Ultrasonographic Scoring System in Diagnosis of Alcoholic Cirrhosis
    Kyoung Min Moon, Soon Koo Baik
    Clinical Ultrasound.2016; 1(2): 92.     CrossRef
  • Hepatoprotective effects ofRubus coreanusmiquel concentrates on liver injuries induced by carbon tetrachloride in rats
    Hyun-Jung Chae, Jung-Eun Yim, Kyung-Ah Kim, Jong-Hee Chyun
    Nutrition Research and Practice.2014; 8(1): 40.     CrossRef
  • Efficacy and Safety of Human Placental Extract for Alcoholic and Nonalcoholic Steatohepatitis: An Open-Label, Randomized, Comparative Study
    Jin Young Choi, Kyeheui Lee, Seung Min Lee, Sun Hong Yoo, Seong Gyu Hwang, Jong Young Choi, Sang Wook Lee, Jae Seok Hwang, Kyoung Kon Kim, Hee Cheol Kang, Gab Jin Cheon, Young Min Park
    Biological and Pharmaceutical Bulletin.2014; 37(12): 1853.     CrossRef
  • Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis
    Kyoung Min Moon, Gaeun Kim, Soon Koo Baik, Eunhee Choi, Moon Young Kim, Hyoun A Kim, Mee Yon Cho, Seung Yong Shin, Jung Min Kim, Hong Jun Park, Sang Ok Kwon, Young Woo Eom
    Clinical and Molecular Hepatology.2013; 19(4): 389.     CrossRef
  • Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
    John FP Bridges, Liming Dong, Gisselle Gallego, Barri M Blauvelt, Susan M Joy, Timothy M Pawlik
    BMC Health Services Research.2012;[Epub]     CrossRef
  • 10,809 View
  • 56 Download
  • Crossref